Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
I. INTRODUCTION

Rotaviruses are one of the most important causes of infectious diarrhea and death in infants and young children throughout the world. Each year, in Asia, Africa, and Latin America, an estimated 3–5 billion cases of gastroenteritis account for 5–10 million deaths (Walsh and Warren, 1979). Since their initial identification as a human pathogen in 1973 (Bishop et al., 1973), rotaviruses have been found to account for 10–20% of gastroenteritis-associated deaths (Snyder and Merson, 1982; Walsh and Warren, 1979). In the United States 70,000–120,000 infants are hospitalized (Ho et al., 1988a; Matson and Estes, 1990) and as many as 200 infants die each year with rotavirus-induced disease (Ho et al., 1988b). Virtually all children, in both developed and
developing countries, are infected with rotaviruses by 2–3 years of age (Urasawa et al., 1984; Yolken et al., 1978a).

The worldwide impact of rotavirus infections has excited interest in disease prevention by immunization. Unfortunately, for the past 20 years, research in the areas of rotavirus immunology and pathogenesis has not yielded a safe, effective, and inexpensive vaccine for universal use. Although development of a successful rotavirus vaccine will depend on addressing a number of issues, this chapter focuses on four important questions that remain unanswered: (1) What is the importance of virus serotype in formulating an optimal vaccine? (2) Which immunological effector arm most likely protects against rotavirus disease? (3) By what means is virus antigen best presented to the host to elicit a protective immune response? (4) What are the advantages and disadvantages of replicating agents (e.g., live, attenuated human or animal rotaviruses, rotavirus reassortants, or vectors expressing individual rotavirus proteins) as compared to nonreplicating agents (e.g., inactivated virus, purified virus proteins, or peptides) as candidate rotavirus vaccines?

II. ROTAVIRUS STRUCTURE

Rotaviruses are a genus within the family Reoviridae. These viruses are nonenveloped and contain an outer capsid and core (reviewed in Estes and Cohen, 1989; Bellamy and Both, 1990). The viral genome consists of 11 separate segments of double-stranded RNA (dsRNA); translation is monocistronic. Two proteins (vp4 and vp7) comprise the rotavirus outer capsid. vp4 is an 88-kDa protein that is the virus hemagglutinin and probable cell attachment protein. vp4 projects as a spike from the virus surface and comprises approximately 2.5% of the viral mass. Cleavage of vp4 by trypsin into two proteins of Mr \(60,000\) (vp5*) and 28,000 (vp8*) is associated with virus entry into cells. vp7 is a 37-kDa glycoprotein that comprises the smooth outer capsid shell and represents approximately 30% of the viral mass. Four proteins (vp1, vp2, vp3, and vp6) comprise the virus core, with vp6 accounting for 50% of the viral mass and 80% of the viral core. Six nonstructural proteins (NS53, NS34, NS35, NS28, NS26, and NS12) are also produced during rotavirus infection (Mattion et al., 1991).

Similar to other members of the Reoviridae, rotaviruses contain a virus-associated RNA transcriptase that synthesizes RNA transcripts that act as mRNA and as templates for the formation of dsRNA. However, rotaviruses are unique among the Reoviridae in that maturation of rotavirus particles occurs in the rough endoplasmic reticulum.
(RER). Immature, single-shelled rotavirus particles bud across the RER, transiently acquiring a membrane. This budding event is mediated by an interaction between vp7 and NS28, the latter acting as a membrane-bound receptor. Both vp7 and NS28 are directed to the ER via specific targeting sequences (reviewed in Both et al., 1993b).

III. IMMUNE RESPONSE IN EXPERIMENTAL ANIMALS

A. Animal Models of Infection and Disease

Rotaviruses infect the young of most species of domestic and laboratory animals (reviewed in Estes et al., 1983). Studies of the histopathological changes induced after rotavirus infection of both large (i.e., calves, lambs, pigs, and dogs) and small (i.e., mice) animals inoculated with homologous host viruses have yielded remarkably similar findings (reviewed in Greenberg et al., 1994). Rotaviruses infect mature villus epithelial cells located at the small intestinal mucosal surface. Infection of epithelial cells causes vacuolization and denudation with replacement of columnar by cuboidal cells. As a result, villi become stunted and shortened. Neither crypt epithelial cells of the small intestine nor mature villus epithelial cells of the large intestine appear to support rotavirus replication. Although rotaviruses may replicate in specialized membranous epithelial cells ("M" cells) that overlay Peyer's patches (Buller and Moxley, 1988), there is scant evidence for an inflammatory response in either Peyer's patches or the intestinal lamina propria during acute infection. The mechanism by which rotavirus induces diarrhea remains unclear (reviewed in Greenberg et al., 1993).

The finding of infectious rotavirus particles only in small intestinal epithelial cells is consistent with the observation that histopathological changes are limited to the intestinal mucosal surface. Rotavirus antigen has been detected by immunofluorescence in Peyer's patches and mesenteric lymph nodes of mice (Dharakhul et al., 1988) and infectious virus has been detected in the mesenteric lymph nodes of calves (Mebus, 1976) after homologous host infection. However, infectious virus has not been clearly detected in the blood or sites distant from the intestine after homologous host infection. Therefore, a successful rotavirus vaccine must induce an immune response that is active at the intestinal mucosal surface.

A number of animal models have been used to study the immune response to infection as well as the capacity of immunization to protect against disease. The ideal model to study the immunological determi-
nants of protection against rotavirus challenge does not exist. Large animals (i.e., calves, pigs, and lambs) infected with cell culture-adapted, homologous or heterologous host rotavirus strains (Bohl et al., 1984; Gaul et al., 1982; Snodgrass and Wells, 1976; Snodgrass et al., 1980; Vonderfecht and Osburn, 1982; Woode et al., 1983) were among the first groups of animals to be studied. The use of cell culture-adapted rotavirus strains allowed for reproducible quantitation of infectious virus and production of adequate quantities of purified virus for in vitro immunological assays. In addition, the extended window of disease in large animals was suitable for studies of active immunization. Unfortunately, the expense and relative inaccessibility of large animals limited the size of studies. The initial choice of large animal models for study was necessitated by problems associated with the use of small animals. Although suckling mice were known to develop rotavirus-induced gastroenteritis (Adams and Kraft, 1967; Banfield et al., 1968), immunological studies in mice were limited by the fact that murine rotaviruses were not adapted to growth in cell culture. This problem was obviated when primate strains (e.g., SA11, RRV) well adapted to growth in cell culture were found to induce clinical symptoms, small intestinal histopathological changes, and a rotavirus-specific immune response similar to that found in large animals (Offit et al., 1984). Because mice were inexpensive and easily maintained, large numbers of animals could be studied. In addition, the use of genetically defined strains of mice allowed for studies of cytotoxic T lymphocytes. Unfortunately, the narrow window of infection in mice (about 10 days) precluded an active immunization scheme. In addition, because induction of disease required large quantities of virus, and disease occurred in the absence of either viral amplification or multiple cycles of virus replication, the degree to which infection of mice with heterologous host (i.e., nonmurine) strains was predictive of events occurring after natural (or homologous host) infection was questioned. The adaptation of murine rotaviruses to growth in cell culture (Greenberg et al., 1986) and the large window of infection (i.e., virus shedding) in adult mice now allow for studies of active immunization in mice (Ward et al., 1990). Similarly, oral inoculation of rabbits with cell culture-adapted lapine strains results in virus shedding over a period of time long enough to include studies of active immunization (Connor et al., 1988). These models allow for determination of immunological correlates of protection by active immunization, using large numbers of genetically defined animals. However, adult mice and rabbits are models for virus shedding but not disease. The degree to which the adult mouse and rabbit models will be predictive of immunological correlates of protection against disease in humans in part depends on
understanding the mechanisms by which virus shedding but not disease is induced in these animals. In retrospect, perhaps the best approach to study the immunological determinants of protection against rotavirus challenge would be to go back to the future. Although limited by expense, large animals (i.e., calves, pigs, and lambs) clearly allow for studies of protection against disease using an active immunization scheme with cell culture-adapted homologous host viruses.

B. B Cell Response

The intestine is a rich source of T and B lymphocytes. Intestinal lymphocytes are located either at the intestinal mucosal surface among villus epithelial cells (intraepithelial lymphocytes), among lymphatic capillaries of the villus below the basement membrane (lamina propria lymphocytes), within lymphatic nodules underlying specialized epithelial cells (M cells) at the base of the villus (Peyer's patch lymphocytes), or within lymph nodes that drain the small intestine (mesenteric lymph nodes). Approximately 50–60% of intraepithelial lymphocytes are T cells, most of which have surface markers consistent with the functions of cytotoxicity and suppression (CD8) (Cerf-Bensussan et al., 1985; Petit et al., 1985); less than 10% of intraepithelial lymphocytes are B cells. In contrast, in the lamina propria and Peyer's patch B cells outnumber T cells by factors of 2:1 and 3:1, respectively. The percentages of T lymphocytes in lamina propria and Peyer's patch bearing CD4 (helper/inducer) or CD8 on their surface are similar.

The humoral immune response, using animals infected with homologous host rotavirus strains, has been the primary focus of a number of studies. Studies of calves, rabbits, and pigs orally inoculated with cell culture-adapted strains (Conner et al., 1991; Corthier and Vannier, 1983; Saif, 1987; Saif et al., 1992; Vonderfecht and Osburn, 1982) and mice with murine strains poorly adapted to growth in cell culture (Sheridan et al., 1983) have produced important information on the site of rotavirus-specific antibody-bearing cells (i.e., B cells and plasma cells) and the isotype and neutralization capacity of these antibodies. Within 10 days of infection, rotavirus-specific binding and neutralizing antibodies of all isotypes are detected both in the serum and in small intestinal fluids; in both sites the appearance of rotavirus-specific IgM precedes the appearance of virus-specific IgA and IgG. At the intestinal surface, rotavirus-specific secretory IgA (sIgA) is the predominant isotype. This finding is consistent with the observation that rotavirus-specific IgA-bearing cells in the lamina propria and mesenteric lymph node outnumber virus-specific IgG- or IgM-bearing
cells by a factor of at least 10:1 (Saif et al., 1992; Vonderfecht and Osburn, 1982). Indeed, in the lamina propria of suckling mice orally inoculated with murine rotavirus, 50% of all IgA-bearing cells are rotavirus specific (Dharakul et al., 1988).

There are also a number of studies examining the immune response to animals orally inoculated with heterologous host viruses (Merchant et al., 1991; Offit and Clark, 1985a,b; Shaw et al., 1993). In mice, for example, heterologous host rotaviruses are better adapted to growth in cell culture than murine strains. The availability of large quantities of purified virus and the capacity to readily evaluate the immune response in vitro with well-characterized strains and large numbers of genetically defined animals has afforded an opportunity to examine the humoral and cellular immune response in detail. However (as stated above), because the biology of heterologous host virus infection differs from that of homologous host virus infection, the results of these studies must be interpreted with caution. Induction of rotavirus gastroenteritis in mice with nonmurine rotaviruses requires an inoculum $10^5$- to $10^6$-fold greater than that required for cell culture-adapted murine rotaviruses (Greenberg et al., 1986). In addition, virus amplification and extended cycles of replication are observed after homologous but not heterologous host infections. Despite these caveats, mice orally inoculated with heterologous host rotaviruses develop a vigorous immune response. Suckling mice orally inoculated with rhesus rotavirus strain RRV develop rotavirus-specific IgM, IgG, and IgA antibody-secreting cells in Peyer's patch and the small intestinal lamina propria in greater numbers than those detected in spleen and mesenteric lymph nodes (Merchant et al., 1991). Virus-specific IgA-secreting cells are detected at far greater frequency in lamina propria and Peyer's patch than are virus-specific IgG- and IgM-secreting cells. Similar to findings with murine viruses in mice, virus-specific IgA accounted for an astounding 50% of all IgA-secreting cells in the lamina propria. Dominance of rotavirus-specific IgA-secreting cells was long-lasting; 1 year after inoculation 17% of all IgA-secreting cells were rotavirus specific (Shaw et al., 1993). Similarly, adult mice orally inoculated with simian strain SA11 generate SA11-specific neutralizing antibodies of both IgA and IgG isotype in both serum and milk (Offit and Clark, 1985a).

Clearly oral inoculation of experimental animals with live homologous or heterologous strains of rotavirus induces antibody-secreting cells among intestinal lymphocytes as well as rotavirus-specific IgA and IgG at the intestinal mucosal surface and in breast milk. However, inoculation by the oral route and inoculation with live rotavirus may
not be required for induction of a vigorous immune response among intestinal lymphocytes or at the intestinal mucosal surface. Adult mice parenterally inoculated with simian strain SA11 develop high titers of virus-specific IgG in milk (Offit and Clark, 1985a). [Because lymphocytes sensitized in the gastrointestinal tract are selectively transported to the mammary gland, milk antibodies are a window to the antibody response occurring at the intestinal mucosal surface (Goldblum et al., 1975).] In addition, parenteral inoculation of mice with noninfectious RRV induced circulating, RRV-specific neutralizing antibodies as well as virus-neutralizing antibodies (presumably IgG) in milk (Offit and Dudzik, 1989a). A direct proof that rotavirus-specific B cells are induced among intestinal lymphocytes (e.g., by B cell enzyme-linked immunospot assay) after parenteral inoculation awaits further experimentation. However, these results are consistent with those previously observed after inoculation of mice with cholera toxin (Fuhrman and Cebra, 1981). Mice parenterally inoculated with cholera toxin develop toxin-specific B cells in the lamina propria at frequencies similar to that observed after oral inoculation; parenteral inoculation induces primarily toxin-specific IgG and oral inoculation induces primarily toxin-specific IgA-bearing cells.

C. T Cell Response

Mice orally inoculated with heterologous host strains of rotavirus develop a vigorous, virus-specific cytotoxic T lymphocyte (CTL) response. Unlike the immune response induced by most virus infections in experimental animals, rotaviruses induce a primary CTL response (i.e., lymphocytes taken directly from the host lyse virus-infected target cells). Primary, rotavirus-specific CTLs are detected at the intestinal mucosal surface (among intraepithelial lymphocytes), in Peyer's patch, lamina propria, mesenteric lymph nodes, and spleen acutely after oral or parenteral inoculation of mice with RRV (Offit and Dudzik, 1989b); this response is inducible, virus specific, and mediated by Thy-1+, major histocompatibility complex (MHC)-restricted cells. Similarly, rotavirus-specific memory CTLs (CTL precursors) appear among intestinal and nonintestinal lymphocyte populations after oral or parenteral inoculation (Offit et al., 1991a). Although route of inoculation determines the frequencies of CTL precursors within a given site acutely after infection (frequencies of RRV-specific CTL precursors were 25- to 30-fold greater after oral than after subcutaneous inoculation), CTL precursors are distributed throughout the lymphoid system several weeks after inoculation (Offit et al., 1991a). Therefore, analo-
ous to induction of virus-specific B cells, oral inoculation of rotavirus may not be necessary to induce virus-specific CTLs or CTL precursors among intestinal lymphocytes.

Activation and differentiation of CD3+CD8+ virus-specific CTL precursors to CTLs is enhanced by exposure to interleukin 2 (IL-2) secreted primarily by CD4+ cells (i.e., helper T cells). Similarly, activation and differentiation of B cells to antibody-secreting cells is enhanced by exposure to IL-4 or IL-5 or both. If T cell help for rotavirus-specific CTL precursors or B cells occurs locally, virus-specific helper T cell activity should be detected in lamina propria and Peyer's patch. However, this may not be the case. After oral inoculation of mice with live rotavirus strain RRV or parenteral inoculation with live or noninfectious RRV, virus-specific helper T cell activity was detected among CD4+ cells by lymphoproliferation assay (LPA) in mesenteric lymph nodes and spleen, but not in lamina propria and Peyer's patch (Riesen and Offit, 1992). Therefore, T cell help for either CTL precursors or B cells may not occur locally but rather in central sites of antigen concentration and presentation (i.e., mesenteric lymph nodes and spleen). Because cytokine secretion may occur in the absence of lymphoproliferation (Evavold and Allen, 1991), these results must be interpreted with caution.

D. Serotype and Structural Specificities of B and T Cell Response

Several studies have determined the rotavirus protein or proteins that evoke antibodies that neutralize virus infectivity in vitro (i.e., determine neutralization phenotype or serotype). Using reassortant rotaviruses made by in vitro coinfection between either two animal strains (Offit and Blavat, 1986; Offit et al., 1986a) or between two human strains or an animal and a human strain (Hoshino et al., 1985), both outer capsid proteins [vp4 (P type) and vp7 (G type)] were found to segregate independently with neutralization phenotype. Although the greatest quantity of rotavirus-specific antibodies is directed against inner capsid proteins (Shaw et al., 1991), there is no evidence that these antibodies are important in neutralization of virus infectivity. Therefore, characterization of rotavirus serotypes is dependent on a definition of both surface proteins (in a manner analogous to the influenza virus hemagglutinin and neuraminidase). To underline further the importance of vp4 and vp7, inoculation of animals with vp4 or vp7 expressed in either a baculovirus, herpes simplex virus, or vaccinia virus vector has been found to elicit virus-specific neutralizing antibodies (Andrew et al., 1990; Dormitzer et al., 1992; Nishikawa et al., 1989). Although studies of reassortant rotaviruses have contributed
to our understanding of B cell specificities, there are two reasons why data generated using this approach should be interpreted with caution. First, rotavirus serotypes were determined in these studies after oral or parenteral inoculation of experimental animals with large quantities of heterologous host strains (in some cases with oil-based adjuvants). Because infection in the wild does not occur either via the parenteral route, with adjuvant, or with large quantities of heterologous host viruses, these studies may not accurately predict the relative importance of vp4 and vp7 in inducing neutralizing antibodies after natural infection. Second, interactions between surface proteins of different strains used to generate reassortants may alter neutralization epitopes present on parental strains (Chen et al., 1992).

The epitopes on rotavirus surface proteins vp4 and vp7 associated with virus neutralization have been identified by sequencing variant viruses selected with monoclonal antibodies (reviewed in Matsui et al., 1989a). Both vp4 and vp7 contain regions that evoke serotype-specific or cross-reactive neutralizing antibodies. However, most monoclonal antibodies directed against vp7 and the vp8* region of vp4 are serotype specific, whereas those directed against the vp5* region of vp4 are cross-reactive (Kitaoka et al., 1986; Mackow et al., 1988; Taniguchi et al., 1988; Matsui et al., 1989b).

Rotavirus-specific CTLs are not serotype specific. Lymphocytes obtained from mice orally inoculated with different rotavirus strains lyse target cells infected with different rotavirus G (vp7) types (Offit and Dudzik, 1988). Although one would have predicted that cross-reactive, rotavirus-specific CTLs would be directed against rotavirus inner capsid proteins (which are antigenically conserved among different rotavirus serotypes), this is not the case. Using vaccinia virus recombinants expressing individual rotavirus proteins, cross-reactive, rotavirus-specific CTLs recognized vp7 better than vp4 or vp6 (Offit et al., 1991b). Similarly, mice orally inoculated with vaccinia virus recombinants expressing vp7 develop rotavirus-specific, cross-reactive CTLs, whereas virus-specific CTLs are not induced after inoculation with recombinants expressing vp4 or vp6 (Offit et al., 1994). Using peptides representing regions on bovine rotavirus vp7, an immunodominant peptide associated with cross-reactive, rotavirus-specific CTL activity was mapped to amino acids 30–41 (Franco et al., 1992). All of these studies were performed in H-2b haplotype mice with a limited number of rotavirus proteins or peptides; the extent to which these findings are predictive of important CTL structural specificities of all rotavirus proteins or of animals or humans representing different genetic backgrounds remains to be determined.
The development of a successful rotavirus vaccine will depend on an understanding of the rotavirus structural and serotype specificities of the humoral and cellular immune response associated with protection against challenge. Many studies have used a passive immunization model of protection to answer these questions. Although passive models of immunization allow for studies of individual effector arms of the immune system, the degree to which passive immunization is predictive of events that occur after natural infection or active immunization is unclear.

Rotavirus-induced gastroenteritis is a common disease among the young of most species of domestic and feral animals (reviewed in Estes et al., 1983). Therefore, in nature, despite the presence of rotavirus-specific neutralizing antibodies in colostrum and milk, breast-feeding does not appear to protect completely against rotavirus-induced disease. However, many studies in experimental animals found that immunization with live or inactivated rotaviruses or rotavirus-specific proteins can induce a level of rotavirus-specific neutralizing antibodies in colostrum and milk that passively protects against disease.

Colostral and milk antibodies probably protect against relatively severe disease under natural conditions of infection. Rotavirus replication in mature villus epithelial cells of the small intestine induces virus-specific B cells among intestinal lymphocytes that travel to the mammary gland (Goldblum et al., 1975). Therefore, colostrum and milk from animals exposed to wild-type viruses contain rotavirus-specific binding and neutralizing antibodies (Woode et al., 1975; Saif et al., 1983). Colostrum obtained from cows previously exposed to wild-type bovine rotavirus protected calves against rotavirus disease when fed in large quantities; smaller quantities of colostrum did not protect against severe disease (Snodgrass and Wells, 1976, 1978a,b; Saif et al., 1983). Protection occurred in the absence of circulating, rotavirus-specific antibodies.

Rotavirus-specific antibodies induced in colostrum and milk after oral or parenteral inoculation of experimental animals clearly protect against disease induced by challenge with a homotypic strain. Cross-fostering studies in mice found that gastrointestinal but not circulating antibodies protected against disease induced by heterologous host rotavirus challenge (Offit and Clark, 1985a). However, presentation of virus antigen to the intestinal mucosal surface was not necessary to induce virus-specific B cells in the mammary gland. For example, parenteral or oral immunization of mice with heterologous host rotaviruses induced high titers of virus-specific neutralizing antibodies.
in milk; oral immunization induced primarily rotavirus-specific sIgA and parenteral immunization induced primarily virus-specific IgG (Offit and Clark, 1985a). Although rotavirus-specific sIgA was approximately 10-fold more potent than IgG \textit{in vivo}, both clearly protected against rotavirus-induced disease (Offit and Clark, 1985a). Similarly, parenteral inoculation of cows with inactivated bovine rotavirus, or of mice with "empty capsid" preparations of SA11 (i.e., containing inner and outer capsid rotavirus proteins but lacking viral genome), or of mice with vaccinia virus or adenovirus vectors expressing SA11 vp7 induced a level of virus-neutralizing antibodies in milk that protected against homotypic rotavirus challenge (Mebus \textit{et al.}, 1973; Sheridan \textit{et al.}, 1984; Snodgrass \textit{et al.}, 1980; Andrew \textit{et al.}, 1992; Both \textit{et al.}, 1993a).

The capacity of rotavirus antibodies to passively protect against challenge by strains heterotypic to the immunizing strain is dependent on the route of inoculation used to generate virus-specific antibodies. Repeated oral inoculation of mice with human and nonmurine animal strains induced a level of homotypic neutralizing antibodies that was approximately 80-fold less than that induced after parenteral inoculation (Offit and Clark, 1985b). Similarly, the level of heterotypic neutralizing antibodies was greater after parenteral than oral inoculation. Protection by passively acquired rotavirus-specific antibodies in milk was induced against both homotypic and heterotypic virus challenge after parenteral immunization but only against homotypic challenge after oral "hyperimmunization." The capacity of parenteral immunization to induce protection against heterotypic virus challenge has been demonstrated by a number of investigators (Lecce \textit{et al.}, 1991; Losonsky \textit{et al.}, 1986a; Schaller \textit{et al.}, 1992; Snodgrass \textit{et al.}, 1977). In addition, parenteral immunization with various combinations of baculovirus-expressed whole vp4, vp6, and vp7, or vp4- or vp7-specific peptides linked to vp6, can induce antibodies that passively protect against homotypic or heterotypic rotavirus challenge (Ijaz \textit{et al.}, 1991; Mackow \textit{et al.}, 1990; Redmond \textit{et al.}, 1993). Presumably, the capacity to induce antibodies directed against broadly cross-reactive epitopes on either vp4 or vp7 or both is dependent on the way in which antigen is initially processed by the immune system (i.e., peritoneal vs intestinal antigen-presenting cells) or the quantity of virus available to the immune system (e.g., absence of inactivation of rotavirus by gastric acid after parenteral as compared to oral inoculation).

The protein and peptide specificities of rotavirus-specific antibodies that passively protect against challenge parallels the specificities of \textit{in vitro} neutralizing antibodies. Animals orally inoculated with reassortant rotaviruses containing either vp4 or vp7 from different parents
induced antibodies that passively protected mice against disease induced by either parental serotype (Offit et al., 1986a). Similarly, monoclonal antibodies directed against regions on vp4 or vp7 that were serotype specific or cross-reactive passively protected animals against challenge with one or several rotavirus serotypes, respectively (Offit et al., 1986b; Matsui et al., 1989b). The parallel between in vivo and in vitro observations with monoclonal antibodies is due to the manner in which studies were performed. Large quantities of rotavirus-specific antibodies derived from ascitic fluids were administered either 30 min before or up to 2 hr after rotavirus challenge. The question of which epitope or epitopes on vp4 or vp7 induce virus-specific memory B cells likely to afford protection against challenge remains unanswered by studies using a passive immunization scheme.

Rotavirus-specific CTLs also passively protect animals against disease. Adoptive transfer of splenic lymphocytes from adult mice orally inoculated with homologous or heterologous host rotavirus strains protected suckling mice against murine rotavirus challenge (Offit and Dudzik, 1990). Protection was MHC restricted, abrogated after elimination of Thy-1- or CD8-bearing cells, and occurred in the absence of circulating, rotavirus-specific antibodies. Similarly, CD8-bearing splenic or small intestinal intraepithelial lymphocytes from adult mice inoculated parenterally with murine rotavirus ablate virus shedding in SCID (severe combined immunodeficiency) mice chronically infected with murine rotavirus; ablation of virus shedding was MHC restricted, broadly cross-reactive among different rotavirus serotypes, and occurred in the absence of neutralizing antibodies in the serum (Dharakul et al., 1990, 1991). In addition, CD8-bearing lymphocytes obtained after inoculation of mice with baculovirus recombinants expressing vp1, vp4, vp6, or vp7 but not vp2, NS53, NS35, or NS28 abrogated murine rotavirus shedding in SCID mice. Rotavirus-specific CTLs induced after oral inoculation with heterologous host strains were directed primarily against vp7 (Offit et al., 1991b; Franco et al., 1992). Last, in vivo depletion of CD8-bearing but not CD4-bearing cells increased rotavirus excretion in calves (Bridger et al., 1992). There remains much to be learned about the memory, trafficking, function, structural specificities, and distribution of rotavirus-specific CTLs after natural infection or immunization.

F. Protection against Disease by Active Immunization

Passive transfer of either rotavirus-specific antibodies or CTLs can protect animals against rotavirus disease. A passive immunization model allows for the evaluation of the protective capacity of individual
effector arms of the immune response. However, the host does not acquire high-titered monoclonal or polyclonal rotavirus-specific neutralizing antibodies or adoptively transferred virus-specific CTLs at or before natural challenge with wild-type virus. Therefore, analyses of the immunological determinants of protection against challenge are best performed in an active immunization scheme. Unfortunately, studies of active immunization have not provided a clear picture of which immunological effector arms are protective against challenge. For example, studies in both calves and mice found that protection against disease induced by homologous host virus after active immunization occurred in the absence of challenge virus-specific neutralizing antibodies in either serum, feces, or intestinal washes (Bridger and Oldham, 1987; Woode et al., 1987; McNeal et al., 1992; Ward et al., 1992a). Fecal antibodies may not accurately predict antibody responses in the small intestine. Alternatively, virus-specific CTLs (which were not measured in these studies) may play an important role in protection after active immunization. In either case, the absence of a reliable and easily obtained immunological marker for protection against disease is a recurrent theme in immunological studies of children and experimental animals and has clearly hampered efforts to develop a successful rotavirus vaccine.

Three important observations made in studies of passive immunization were confirmed using an active immunization scheme. First, protection against homotypic challenge can be induced after oral immunization. Mice, pigs, calves, and rabbits were protected against disease induced by homologous host viruses after oral inoculation with strains homotypic but not heterotypic to the challenge virus (Woode et al., 1978, 1983, 1987, 1989; Gaul et al., 1982; Bohl et al., 1984; Hoshino et al., 1988; Hambræus et al., 1989; Ward et al., 1990, 1992a; Conner et al., 1991). However, ablation of virus shedding after heterotypic challenge by active oral immunization has also been demonstrated (Burns et al., 1992). Second, neither inoculation with live rotavirus nor presentation of antigen to the intestinal mucosal surface is necessary for induction of protection against rotavirus disease. Intraperitoneal inoculation of mice with purified, inactivated murine rotavirus without adjuvant ablated rotavirus shedding after murine rotavirus challenge (McNeal et al., 1992). In addition, parenteral inoculation of virus-like particles containing baculovirus-expressed vp2, vp4, vp6, and vp7 ablated rotavirus shedding after heterotypic challenge (Crawford et al., 1992). Third, protection against heterotypic challenge is probably best induced after parenteral inoculation (Wyatt et al., 1979, 1983; Zissis et al., 1983; McNeal et al., 1992; Ward et al., 1992a).

The structural specificities of the humoral immune response associ-
ated with protection against challenge after active immunization have been defined (Hoshino et al., 1988). Similar to studies in vitro and those using a passive immunization scheme with polyclonal or monoclonal antibody preparations, both vp4 and vp7 independently evoke antibodies that are associated with protection against challenge. Oral inoculation of piglets with reassortant rotaviruses containing genes that encoded vp4 or vp7 from two serotypically distinct (and not mutually cross-protective) porcine rotaviruses protected against challenge with either parent.

IV. IMMUNE RESPONSE IN INFANTS AND YOUNG CHILDREN

A. Infection and Disease in Humans

The clinical presentation of children admitted to the hospital with rotavirus-induced disease is not clearly distinct from other infectious causes of gastroenteritis. Rotavirus disease affects children primarily between 6 and 18 months of age (Kapikian et al., 1976) and in temperate climates occurs almost exclusively during the winter months (LeBaron et al., 1990). The disease is characterized by the sudden onset of watery diarrhea, fever, and vomiting. The presence of vomiting and moderate to severe dehydration is significantly more common in patients excreting rotavirus than in those who are not (Rodriguez et al., 1977); this fact accounts in large part for the disproportionate number of hospitalizations for rotavirus-induced gastroenteritis as compared to gastroenteritis caused by other agents.

The epidemiology and clinical presentation of rotavirus-induced disease provide a number of clues to host factors associated with amelioration of acute infection and protection against reinfection. First, rotavirus replication probably occurs solely in small intestinal villus epithelial cells (Bishop et al., 1973; Davidson et al., 1975). Although there are a number of case reports claiming an association of rotavirus infections with diseases distant from the intestinal tract (Salmi et al., 1978; Wong et al., 1984; Rotbart et al., 1983, 1988; Hattori et al., 1992; Grunow et al., 1985; Santosham et al., 1983; Matsumo et al., 1983; Yolken and Murphy, 1982; Whorwell et al., 1977), there remains no clear evidence that rotavirus replication is supported by cells other than those that line the small intestine or that viremia is an important component in the pathogenesis of rotavirus-induced disease. Therefore, protection against reinfection is dependent on induction of an immune response active at the intestinal mucosal surface. Second,
children with immunodeficiency syndromes develop prolonged shedding of rotavirus after acute infection (Saulsbury *et al.*, 1980; Wood *et al.*, 1988). Therefore, amelioration of acute infection is at least in part mediated by immunological factors.

**B. Protection against Disease by Breast-Feeding and Passive Immunization**

Virtually all women, independent of socioeconomic background, have rotavirus-specific binding antibodies (primarily sIgA) and rotavirus-specific neutralizing antibodies in colostrum and milk (Yolken *et al.*, 1978b; Cukor *et al.*, 1979; Otnaess and Orstavik, 1980; Bell *et al.*, 1988; Ringenbergs *et al.*, 1988). Levels of virus-specific binding and neutralizing antibodies appear to decline in milk during the first 6 months of life (Yolken *et al.*, 1978b; Ringenbergs *et al.*, 1988). The presence of virus-specific neutralizing antibodies may in part be responsible for the decreased incidence of symptomatic rotavirus infection in early infancy (Perez-Schael *et al.*, 1984; Chrystie *et al.*, 1978).

Breast-feeding appears to protect against relatively severe rotavirus disease in infants (Mata *et al.*, 1983; Duffy *et al.*, 1986a,b; Zheng *et al.*, 1992). Higher levels of rotavirus-specific neutralizing antibodies in colostrum and milk are detected in mothers of uninfected as compared to infected neonates (Zheng *et al.*, 1992). However, unlike enteric infections such as cholera (Glass *et al.*, 1983) and shigella (Stoll *et al.*, 1982) (in which the relationship between breast-feeding and protection against disease is clear-cut), a number of studies failed to demonstrate an association between breast-feeding and protection against rotavirus disease (Cushing and Anderson, 1982; Totterdell *et al.*, 1982; Weinberg *et al.*, 1984; Glass *et al.*, 1986; Blake *et al.*, 1993). Similar to passive protection studies performed in animals (Offit and Clark, 1985b), the capacity of colostrum or milk to protect against disease is probably dependent on the titer of serotype-specific neutralizing antibodies. Levels of neutralizing antibodies in milk that are protective against challenge may only occasionally be reached after natural infection. Therefore, studies including low numbers of infants may give conflicting results. In addition, part of the variance among these studies may be attributed to differences in (1) definition of protection against challenge (i.e., protection against infection vs protection against relatively severe disease), (2) sensitivity of assays used to correlate rotavirus-specific antibodies with protection (i.e., binding vs neutralizing antibodies), (3) nutritional status of the study population, and (4) study design. To date, studies of protection by breast-feeding
have not included an analysis of the relationship between serotype-specific neutralizing antibodies in milk and characterization of the P (vp4) and G (vp7) types of the infecting strains.

Protection against rotavirus infection and relatively severe disease can be afforded by oral administration of either serum immunoglobulins or bovine milk containing high titers of rotavirus-specific neutralizing antibodies (Barnes et al., 1982; Davidson et al., 1989). However, amelioration of acute disease in infants (as distinct from prophylactic protection against disease) is not afforded by passive administration of bovine milk containing high titers of rotavirus-neutralizing antibodies (Hilpert et al., 1987). It is unclear whether passive protection is afforded by transplacental transfer of maternal, rotavirus-specific IgG (Totterdell et al., 1980; Jayashree et al., 1988; Bernstein et al., 1990b). These findings are almost identical to those observed in mice; oral inoculation of mice with monoclonal antibody preparations containing high levels of neutralizing activity protected against disease when administered within 2 hr of infection, but did not ameliorate acute disease (Offit et al., 1986b). In both mice and humans, rotavirus replication in the small intestine is limited to several days, and administration of antibodies at the time of clinical disease is probably too late to alter the clinical course. However, in children with immunodeficiency disorders (in whom rotavirus replication may occur over many weeks or months), rotavirus-specific immunoglobulin preparations administered orally may ablate shedding and ameliorate disease (Guarino et al., 1991).

C. Response to Natural Infection

The humoral immune response of infants and young children following rotavirus infection is similar to that observed in animals (Davidson et al., 1983; Riepenhoff-Talty et al., 1981; Grimwood et al., 1988; Aiyar et al., 1990). Within the first week of illness rotavirus-specific IgM is detected in the duodenal fluid and serum. Both 1 and 4 months after infection, rotavirus-specific IgG and sIgA are detected in the duodenal fluid and rotavirus-specific IgG and monomeric IgA are detected in the serum. Levels of salivary and fecal IgA are predictive of those obtained in duodenal fluid. One year after infection, rotavirus-specific IgG but not IgA is detected in the serum, and neither IgG nor IgA is detected at the mucosal surface. Because of its persistence in serum after natural infection, circulating rotavirus-specific IgG provides an excellent marker for previous exposure to rotavirus in older infants and children. In addition, fecal or duodenal IgA provides an excellent marker for recent infection (either primary infection or reinfection) because of
the relatively rapid disappearance of this isotype from the intestinal mucosal surface (Coulson et al., 1990). Similar to infants and older children, neonates (i.e., infants less than 1 month of age) develop rotavirus-specific IgM and IgA in the circulation after either symptomatic or asymptomatic infection (Bishop et al., 1990; Losonsky and Reymann, 1990).

Rotavirus-specific helper T cells are detected in the circulation within several weeks of primary, symptomatic infection (Offit et al., 1993). This finding is consistent with the observation that lymphocytes originating in the murine small intestine migrate to the circulation after entrance through the thoracic duct (Guy-Grand et al., 1978) and, therefore, similar to rotavirus-specific sIgA, rotavirus-specific T cells probably provide a window to intestinal T cell responses. There are no studies evaluating the relative contributions of T helper type 1 (T<sub>H</sub>-1) or T<sub>H</sub>-2 T cell or CTL responses in children after natural infection.

Although understanding may be critical to development of a successful vaccine, the P (vp4)- and G (vp7)-type specificities of the humoral immune response after natural infection remain unclear. Sera from animals parenterally inoculated with human rotaviruses have been used to define at least nine different human rotavirus G types (G types 1–4, 6, 8, 9, 10, and 12). G types 1–4 are the most important G types isolated in epidemiological studies in both developed and developing countries; G type 1 is the most common (Flores et al., 1988; Matson et al., 1990b; Padilla-Noriega et al., 1990; Bishop et al., 1991; Bingnan et al., 1991; Ahmed et al., 1991; Noel et al., 1991; Woods et al., 1992). Hybridization analysis has been used to distinguish at least five human rotavirus P types (Gentsch et al., 1992; Gorziglia et al., 1990; Estes and Cohen, 1989). The P- and G-type specificities of the humoral immune response after natural infection have been difficult to determine for a number of reasons. First, different human rotavirus P genotypes have only recently been identified. Second, rotavirus strains associated with infection are rarely characterized by both P and G type. Third, there may be important antigenic differences between P and G types of the infecting strains as compared to reference strains used in in vitro assays of neutralizing activity. Fourth, the specificities of the immune response may differ after primary versus subsequent infection. The presence of passively transferred maternal rotavirus-specific IgG has made it difficult to determine whether an infant has been previously exposed to rotavirus. Fifth, use of reassortant viruses to determine P- and G-type specificities may be undermined by differences in vp4 or vp7 phenotype determined by the parent (or background) strain (Chen et al., 1992). Finally, use of epitope-blocking analysis to determine serotype specificities is hampered by the use of
monoclonal antibodies representing some but probably not all neutralization regions on vp4 or vp7. Therefore, epitope blocking assays may not accurately predict neutralization assays (Matson et al., 1992). Despite these problems, a preponderance of evidence supports the hypothesis that vp4 may be more important than vp7 in evoking virus-specific neutralizing antibodies during natural infection (Clark et al., 1985; Puerto et al., 1987; Ward et al., 1988; Gerna et al., 1990; Brussow et al., 1990; Offit et al., 1993; Ward et al., 1993). Studies of infants and young children found that neutralizing antibodies generated after natural infection were not specific for G type (Clark et al., 1985; Puerto et al., 1987; Gerna et al., 1990) and were directed against vp4 (Brussow et al., 1990; Offit et al., 1993; Ward et al., 1993). In addition, adults orally inoculated with a human rotavirus strain develop higher levels of neutralizing antibodies directed against vp4 than vp7 (Ward et al., 1988). The capacity of the humoral immune response to distinguish different human rotavirus P types after natural infection has not been determined.

Studies of the humoral and cellular immune response in infants and young children after natural infection provide three important pieces of information. First, circulating rotavirus-specific IgA and virus-specific helper T cells probably provide a window to immune responses occurring among intestinal lymphocyte populations. Detection of rotavirus-specific sIgA in duodenal fluid and feces simultaneous to detection of rotavirus-specific monomeric IgA in the serum is compatible with the observation that IgA-bearing, antigen-specific B cells and plasma cells are detected concomitantly in the lamina propria and circulation acutely after oral inoculation of adult volunteers with cholera or Streptococcus mutans (Quiding et al., 1991; Czerkinsky et al., 1987). Second, the rotavirus-specific sIgA response induced at the intestinal mucosal surface after natural infection may be short lived (Davidson et al., 1983; Coulson et al., 1990). This finding has enormous implications on the timing of administration of rotavirus vaccine candidates. Third, vp4 is perhaps the most important protein in evoking neutralizing antibodies after natural infection. It is, therefore, of great importance to determine whether different human rotavirus P types distinguished by hybridization analysis are also distinguished by neutralizing antibodies generated after primary infection.

D. Protection against Disease by Natural Infection

Natural infection with rotaviruses protects against relatively severe disease caused by reinfection. Neonates infected within the first 2
weeks of life are protected against relatively severe disease but not reinfection (Bishop et al., 1983). Similarly, infants and young children are protected against symptomatic disease after primary infection, independent of whether the primary infection was symptomatic or asymptomatic (Bernstein et al., 1990a; Bishop et al., 1990); protection lasted for at least 2 years. On the other hand, symptomatic reinfection 1 year following primary infection (even with the same serotype) is well described (Yolken et al., 1978a; Black et al., 1982; Bishop et al., 1983; Mata et al., 1983; Chiba et al., 1986; Ward et al., 1986, 1989; Linhares et al., 1988; Georges-Courbot et al., 1988; Friedman et al., 1988; Grinstein et al., 1989; Reves et al., 1989; O’Ryan et al., 1990; De Champs et al., 1991). Similarly, 10–20% of adults in contact with rotavirus-infected infants and young children develop rotavirus-induced gastroenteritis (Kim et al., 1977; Haug et al., 1978; Rodriguez et al., 1979, 1987). The attack rate in adults is similar to that observed in infants and young children. Therefore, although the data are somewhat contradictory, protection against rotavirus disease induced by natural infection may in many cases be short lived. It remains unclear whether serotype is important in protection against reinfection (Chiba et al., 1986; Ward et al., 1992b).

There remains no definitive immunological correlate of protection against rotavirus disease. However, protection is probably best predicted by the immunological response occurring at the intestinal mucosal surface. High levels of fecal, rotavirus-specific IgA correlate with protection against disease (Coulson et al., 1992; Matson et al., 1993). Of interest, high levels of rotavirus-specific IgG in serum also correlate with protection against relatively severe disease (Black et al., 1982; Ryder et al., 1985; Clemens et al., 1992). However, although the quantity of serotype-specific neutralizing antibodies in serum directed against the challenge virus has been found to correlate directly with protection against disease (Chiba et al., 1986) this has not been a consistent finding (Ward et al., 1992b). Possibly, high levels of rotavirus-specific IgG in serum are predictive of persistence of rotavirus-specific sIgA at the intestinal mucosal surface. The short-lived sIgA response (in contrast to the relative persistence of circulating, rotavirus-specific IgG) is consistent with the often short-lived nature of protection against disease induced by natural infection, and further supports the correlation between rotavirus-specific sIgA at the intestinal surface and protection against disease. It would be of interest to determine the correlation between the serotype specificity of intestinal, rotavirus-specific IgA and protection against challenge of known serotype.
E. Response to and Protection against Disease by Active Immunization

Over the past 10 years thousands of infants and young children have been orally inoculated with candidate rotavirus vaccines in trials of protective efficacy (see Table I). Similar to the use of cowpox to prevent smallpox infection and *Mycobacterium bovis* (i.e., bacillus Calmette-Guérin) to prevent *Mycobacterium tuberculosis* infection, heterologous host rotaviruses have been used to prevent rotavirus infections. Non-human strains have included a primate strain [rhesus rotavirus strain MU18006 (RRV)] isolated from a rhesus monkey, and bovine strains that have been passaged many [Nebraska calf diarrhea virus (NCDV), strain RIT 4237] or few [Wistar calf 3 (WC3)] times in cell culture. In addition, reassortant rotaviruses containing 1 gene encoding outer capsid protein vp7 from human rotaviruses and 10 genes from either the bovine or simian rotavirus parent have been studied.

Similar to natural infection, oral inoculation of infants and young children with NCDV (strain RIT 4237) induces rotavirus-specific IgG and IgM and virus-specific neutralizing antibodies in serum (Vesikari et al., 1985a, 1986; Maldonado et al., 1986). In infants not previously exposed to rotavirus, immunization induces antibodies that neutralize NCDV but not human serotypes G1 or G2 (Vesikari et al., 1983). In Finland, 40–50% of infants were protected against rotavirus-induced disease and 80–90% were protected against relatively severe disease within 1 year after oral inoculation with one or two doses of NCDV (Vesikari et al., 1984, 1985b, 1991a). Similarly, three doses of NCDV in Peru induced protection against severe disease (Lanata et al., 1989). On the other hand, studies in Rwanda (DeMol et al., 1986) and Gambia (Hanlon et al., 1987) failed to show protection against disease.

WC3, like NCDV, is not well adapted to growth in the human intestinal tract. Only about 20% of infants orally inoculated with $10^7$ plaque-forming units (PFU) of WC3 shed virus in the feces and none develop signs or symptoms of gastrointestinal infection. Similar to NCDV, WC3 induces WC3-specific but not human serotype G1-, G2-, G3-, or G4-specific neutralizing antibodies in the serum (Clark et al., 1986; Bernstein et al., 1990b). In addition, WC3 inoculation induces a rotavirus-specific IgA response in serum and feces (Bernstein et al., 1990b). In Philadelphia, 75% of infants orally inoculated with one dose of WC3 were protected against rotavirus disease induced by serotype G1. One hundred percent of these infants were protected against severe disease; protection occurred in the absence of G1-specific neutralizing antibodies in serum (Clark et al., 1988). Statistically significant protection against disease was not observed in trials performed in
TABLE I
PROTECTION AGAINST ROTAVIRUS DISEASE INDUCED BY ACTIVE IMMUNIZATION WITH EITHER ANIMAL OR HUMAN ROTAVIRUSES OR ANIMAL × HUMAN REASSORTANT ROTAVIRUSES

| Candidate vaccine | Site             | Number of subjects | Number of doses | Protection against severe disease (%) | Protection against all disease (%) | Ref.                        |
|-------------------|------------------|--------------------|----------------|---------------------------------------|-----------------------------------|-----------------------------|
| Bovine            |                  |                    |                |                                       |                                   |                             |
| NCDV              | Finland          | 178                | 1              | 88                                    | 50                                | Vesikari et al. (1984)      |
|                   |                  | 328                | 2              | 82                                    | 58                                | Vesikari et al. (1985b)     |
|                   | Rwanda           | 245                | 1              | 0                                     | 0                                 | DeMol et al. (1986)         |
|                   | Gambia           | 185                | 3              | 31                                    | 0                                 | Hanlon et al. (1987)        |
|                   | Peru             | 391                | 3              | 75                                    | 40                                | Lanata et al. (1989)        |
|                   | Finland          | 252                | 2              | 89                                    | 43                                | Vesikari et al. (1991a)     |
| WC3               | Philadelphia, PA | 104                | 1              | 100                                   | 76                                | Clark et al. (1988)         |
|                   | Cincinnati, OH   | 206                | 1              | 41                                    | 17                                | Bernstein et al. (1990b)    |
| WC3               | Central African  | 472                | 2              | 36                                    | 0                                 | Georges-Courbot et al. (1991) |
|                   | Republic         |                    |                |                                       |                                   |                             |
| Bovine × human reassortants |          |                    |                |                                       |                                   |                             |
| WC3-G1            | Philadelphia     | 77                 | 2              | 100                                   | —                                 | Clark et al. (1990)         |
| Human             |                  |                    |                |                                       |                                   |                             |
| M37               | Finland          | 282                | 1              | —                                     | 0                                 | Vesikari et al. (1991b)     |

(continued)
| Candidate vaccine | Site            | Number of subjects | Number of doses | Protection against severe disease (%) | Protection against all disease (%) | Ref.                      |
|-------------------|----------------|--------------------|----------------|---------------------------------------|-----------------------------------|---------------------------|
| Simian            | RRV Maryland   | 27                 | 1              | —                                     | 100                               | Rennels et al. (1986)     |
|                   | RRV Nashville, TN | 50                 | 1              | —                                     | 50                                | Wright et al. (1987)      |
|                   | RRV Venezuela   | 247                | 1              | 100                                   | 68                                | Flores et al. (1987)      |
|                   | RRV Rochester, NY | 176                | 1              | 0                                     | 0                                 | Christy et al. (1988)     |
|                   | RRV Maryland    | 114                | 1              | —                                     | 29                                | Rennels et al. (1990)     |
|                   | RRV Finland     | 200                | 1              | 67                                    | 38                                | Vesikari et al. (1990)    |
|                   | RRV Sweden      | 106                | 1              | 80                                    | 48                                | Gothefors et al. (1990)   |
|                   | RRV Venezuela   | 320                | 1              | 90                                    | 64                                | Perez-Schael et al. (1990a) |
|                   | RRV Rochester, NY | 223                | 1              | —                                     | 66                                | Madore et al. (1992)      |
| Simian × human reassortants | RRV-G1 Finland | 359                | 1              | —                                     | 67                                | Vesikari et al. (1992)    |
|                   | RRV-G2          | 1                  | —              | 65                                    | Vesikari et al. (1992)            |
|                   | RRV-G1 Rochester, NY | 223                | 1              | —                                     | 77                                | Madore et al. (1992)      |
|                   | RRV-G1 United States | 903                | 1              | —                                     | 65                                | Sack et al. (1992)        |
|                   | RRV-G1          | 1                  | —              | 63                                    | Sack et al. (1992)                |
|                   | RRV-G2          |                    |                |                                       |                                   |                          |
|                   | RRV (G3)        |                    |                |                                       |                                   |                          |
|                   | RRV-G4          |                    |                |                                       |                                   |                          |
Cincinnati (Bernstein et al., 1990b) and Bangui (Georges-Corbot et al., 1991). However, in both Cincinnati and Bangui protection against G1 and G3 rotavirus challenge was associated with high levels of WC-3-specific neutralizing antibodies in serum. Explanations for the differences in results between trials in Philadelphia and Cincinnati remain unclear. The poor results obtained in the trial of WC3 in Central Africa are similar to those for NCDV in Rwanda and Gambia. Difficulties in induction of virus-specific immunity and protection against disease in developing countries has also been observed with oral poliovirus vaccine and may relate to either interfering rotavirus-specific antibodies in breast milk, concomitant and competitive infections of the gastrointestinal tract, relative malnutrition of the host leading to a poorer virus-specific immune response, or other unknown causes.

In an attempt to enhance protection against disease by WC3, a gene encoding human rotavirus outer capsid protein vp7 (strain WI79, G1) was used to replace the gene encoding WC3 vp7 (G6) in a reassortant strain (WC3-G1). In a small trial performed in Philadelphia, 100% of infants were protected against rotavirus disease induced by G1 or G3 strains (Clark et al., 1990). However, although 97% of vaccinees developed WC3-virus-specific neutralizing antibodies in serum, only 22% developed neutralizing antibodies to G1 rotavirus (strain WI79). The immunological basis of the heterotypic protection observed in this trial remains unclear.

Simian strain RRV is better adapted to growth in the human intestinal tract than either bovine strain NCDV or WC3 (Vesikari et al., 1986). Strain RRV is consistently shed in the feces of orally immunized infants and young children. In addition, RRV is G type 3. Similar to the bovine strains, oral inoculation of infants and young children with RRV induced rotavirus-specific IgG, IgA and IgM in serum, rotavirus-specific IgA in feces, and RRV- but not G1-specific neutralizing antibodies in serum (Losonsky et al., 1986b, 1988; Anderson et al., 1986; Perez-Schael et al., 1987; Rennels et al., 1987; Christy et al., 1988). Similar to WC3, oral inoculation of RRV in infants and young children inconsistently protected against rotavirus disease in developed countries (Rennels et al., 1986, 1990; Wright et al., 1987; Christy et al., 1988; Vesikari et al., 1990; Gotheors et al., 1990). However, unlike WC3, RRV has been shown to protect against severe disease in developing countries (Flores et al., 1987; Perez-Schael et al., 1990a). Strain RRV induced protection against either the G1 or G3 strain (Vesikari et al., 1990; Gotheors et al., 1990). Similar to the bovine strains, the immunological basis of protection by RRV against heterotypic challenge is not associated with the presence of heterotypic neutralizing antibodies in serum. However, consistent with heterotypic protection,
blocking antibodies directed against a broadly cross-reactive epitope (on vp4) were found in infants orally inoculated with RRV (Shaw et al., 1987); antibodies directed against heterotypic epitopes on either vp4 or vp7 were not found in other studies (Green et al., 1990; Padilla-Noriega et al., 1992).

Similar to the bovine strains, protection against challenge after immunization with RRV was induced against human serotypes (e.g., G1) distinct from RRV. To further enhance the response against human G types, single gene reassortant viruses were constructed that expressed vp7 from human G type 1, 2, or 4 (Midthun et al., 1985, 1986). Oral inoculation of infants with RRV × human reassortant strains induced rotavirus-specific IgA and RRV-specific neutralizing antibodies in serum (Flores et al., 1989; Midthun et al., 1989; Perez-Schael et al., 1990b; Wright et al., 1991; Dagan et al., 1992). However, neutralizing antibody responses directed against G type 1, 2, or 4 after immunization with reassortant viruses containing these G types were not dramatically greater than heterotypic neutralizing antibody responses obtained after immunization with RRV alone (Flores et al., 1989; Perez-Schael et al., 1990b; Dagan et al., 1992). These data are consistent with previously discussed observations that vp4 may be more immunogenic than vp7 after either natural infection or immunization (see Section IV,C). Immunization with RRV reassortant rotaviruses expressing human G type 1, 2, or 4 induced protection against rotavirus disease (caused predominantly by G1 rotavirus strains) in 63–77% of vaccinees within the first year (Vesikari et al., 1992; Madore et al., 1992; Sack, 1992). Therefore, protection against disease induced by reassortant viruses was not significantly greater than that found after immunization with RRV (see Table I). Protection against disease 1–2 years after immunization was less than that observed during the first year (Vesikari et al., 1992; Madore et al., 1992; Sack, 1992).

The only human rotavirus studied as a possible vaccine candidate was isolated from an asymptomatic Venezuelan newborn (strain M37). Immunization of infants with M37 induced M37-specific neutralizing antibodies in serum (Midthun et al., 1991; Vesikari et al., 1991b). However, oral inoculation of infants with M37 did not induce protection against rotavirus disease (Vesikari et al., 1991b).

Studies of adults orally inoculated and challenged with rotaviruses have provided important information on the immunological correlates of protection against challenge. Unlike studies of young infants, studies in adults inoculated with rotaviruses represent responses to reinfection and not primary infection. Similar to observations in infants and young children, reinfection induces neutralizing antibodies that broadly cross-react with rotavirus serotypes distinct from the immu-
nizing serotype (Kapikian et al., 1983; Ward et al., 1986); cross-reactive neutralizing antibodies generated in serum block a heterotypic epitope located on vp4 (Green and Kapikian, 1992). Protection against disease correlated with challenge virus-specific neutralizing antibodies in jejunum fluid (Ward et al., 1989) and epitope-blocking antibodies in serum directed against either heterotypic epitopes (on vp4) or homotypic epitopes (on vp7) (Green and Kapikian, 1992).

Comparison of results of rotavirus vaccine trials (see Table I) is difficult for a number of reasons. Differences among studies include dose of virus administered, dosing schedules, age of child at time of inoculation, feeding regimens of mothers (breast-fed vs non-breast-fed), and biology of bovine, simian, and human rotaviruses. Despite these differences, a remarkably similar pattern of results allows one to draw the following conclusions. First, protection against disease caused by strains heterotypic to the immunizing virus is induced after immunization with either bovine or simian strains. These findings were not clearly predicted by studies in animal models. Second, protection against rotavirus-induced disease often occurs in the absence of virus-specific neutralizing antibodies in serum directed against the challenge virus. Third, infants previously exposed to rotaviruses are more likely to develop antibodies that neutralize rotavirus strains serotypically distinct from the immunizing strain than unexposed infants. Finally, animal × human reassortant viruses (expressing human G types) do not clearly induce a level of protection against disease greater than that observed after immunization with the parent bovine or simian strains.

V. Summary

Although studies of rotavirus immunity in experimental animals and humans have often yielded conflicting data, a preponderance of evidence supports the following answers to the questions initially posed.

1. What is the importance of virus serotype in formulating an optimal vaccine? Both vp4 and vp7 induce virus-neutralizing antibodies after either natural infection or immunization; the capacity of vp4 to induce rotavirus-specific neutralizing antibodies is probably greater than that of vp7. However, protection against disease after immunization of infants and young children is induced by strains heterotypic to the challenge virus (e.g., immunization with WC3 induces protection against disease induced by serotypically distinct human G1 strains). In
addition, oral inoculation of infants with primate or bovine reassortant rotaviruses containing genes that encode human vp7 has not consistently induced a higher level of protection against challenge than that induced by parent animal rotaviruses (see Table I). Therefore, although vp4 or vp7 or both are probably important in inducing protection against challenge, it has not been clearly demonstrated that inclusion of the epidemiologically important human (as distinct from animal) P or G type is important in protection against human disease.

2. Which immunological effector arm most likely protects against rotavirus disease? No immunological effector arm clearly explains protection against heterotypic challenge. Protection against disease is not predicted by rotavirus-specific neutralizing antibodies in serum. Rotavirus-specific, binding sIgA in feces [detected by enzyme-linked immunosorbent assay (ELISA)] induced after natural infection does correlate with protection against disease induced by subsequent infection. However, protection after immunization with WC3 may occur in the absence of a detectable fecal sIgA response. The relationship between rotavirus-binding sIgA and sIgA-mediated neutralizing activity directed against the challenge virus remains to be determined. Binding rotavirus-specific sIgA in feces detected by ELISA may only be a correlate of other events occurring at the intestinal mucosal surface. The presence of broadly cross-reactive, rotavirus-specific CTLs at the intestinal mucosal surface of mice acutely after infection is intriguing. It would be of interest to determine the degree to which the presence of cross-reactive, rotavirus-specific CTLs in the circulation is predictive of the presence of virus-specific CTLs among intestinal lymphocytes and protection against challenge. Unfortunately, studies of virus-specific CTLs are difficult to perform in children.

3. By what means is virus antigen best presented to the host to elicit a protective immune response? Oral inoculation may not be necessary to induce a protective, virus-specific immune response at the intestinal mucosal surface. Parenteral inoculation of experimental animals with rotavirus induces an immune response at the intestinal mucosal surface (probably virus-specific IgG) that is protective against challenge.

4. What are the advantages and disadvantages of replicating agents (i.e., live, attenuated human or animal rotaviruses, rotavirus reassortants, or vectors expressing individual rotavirus proteins) as compared to nonreplicating agents (e.g., inactivated virus, purified virus proteins, or peptides) as candidate rotavirus vaccines? Induction of a rotavirus-specific protective immune response is probably associated with the presence of virus-specific T and B cells in intestinal lymphoid tissues and virus-specific sIgA or IgG at the intestinal mucosal surface. There is some experimental evidence to support the hypothesis that
neither rotavirus replication nor presentation of rotavirus antigen to the intestinal mucosal surface is necessary to achieve this aim. Similarly, parenteral inoculation of children with inactivated poliovirus reduces virus shedding induced by subsequent oral inoculation with live, attenuated poliovirus (Faden et al., 1990; Onorato et al., 1991). Therefore, parenteral immunization of either replicating or non-replicating agents may prove to be an acceptable vaccine strategy.

VI. Future Directions

Ten years of studying the immune response of infants and young children to natural infection and immunization with rotaviruses has yielded some good news and some bad news. The good news is that protection induced by natural infection is in many cases complete and long-lasting (i.e., for at least 2 years) (Bishop et al., 1983, 1990; Bernstein et al., 1990a). The bad news is that protection against disease by natural infection may also be short lived and incomplete (Yolken et al., 1978a; Black et al., 1982; Bishop et al., 1983; Mata et al., 1983; Chiba et al., 1986; Ward et al., 1986, 1989; Linhares et al., 1988; Georges-Courbot et al., 1988; Friedman et al., 1988; Grinstein et al., 1989; Reves et al., 1989; O’Ryan et al., 1990; De Champs et al., 1991). Consistent with incomplete and short-lived protection after natural infection is the disappointing finding that oral inoculation with RRV (which occasionally induces mild disease and like natural infection clearly replicates in the intestine) does not consistently induce protection against challenge. The daunting task for rotavirus researchers may be to develop a vaccine that is in many cases better at inducing protection against disease than natural infection. There are currently about 20 vaccines used for active immunization in humans—only one (Haemophilus influenzae type B) induces protection against disease better than natural infection.

Why does infection with some viruses (e.g., measles, mumps, rubella, poliovirus) induce protection that is life-long and complete, whereas infection with others [e.g., rotavirus, influenza virus, respiratory syncytial virus (RSV)] induces protection that may be short lived and incomplete? The answer may be in part that rotavirus, influenza virus, and RSV are all superficial mucosal infections with short incubation periods (i.e., 2–5 days); virus is rarely detected in the blood, and replication at sites distant to the mucosal surface is not an important part of viral pathogenesis. In contrast, viremia (and replication distant from the site of primary replication) occurs in measles, mumps, rubella, and poliovirus infections; consequently, incubation periods are
long (i.e., 8–14 days). Because of these differences in incubation periods, activation and differentiation of virus-specific memory T and B cells are probably more important in protection against "systematic" infections than against "superficial" mucosal infections. Protection against superficial mucosal infections may simply be mediated by the level of virus-specific immunity (e.g., sIgA or IgG, or virus-specific CTLs) present at the mucosal surface at the time of infection.

The best rotavirus vaccine will probably be one that induces a protective level of virus-specific immunity at the intestinal mucosal surface from 6 months to 3 years of age. (Dehydration secondary to rotavirus-induced gastroenteritis is most commonly observed between 6 and 24 months of age and less commonly beyond 3 years of age.)

There are several approaches that are currently being explored. (1) Oral inoculation of infants (beginning at 2–4 months of age) with either attenuated human, animal, or animal × human reassortant rotaviruses by schedules that would include booster immunizations immediately prior to the time at which children are likely to be exposed: If protection against disease induced by immunization or natural infection is short lived, immunization schedules similar to the oral poliovirus vaccine (i.e., 2, 4, and 6 months of age) may result in intervals between immunization and natural infection of up to 10 months. (2) Inclusion of genes that encode human vp4 (P type) in reassortant viruses: vp4 may more likely to induce rotavirus-neutralizing antibodies than vp7. Whether inclusion of vp4 in reassortant viruses induces protection better than that achieved with reassortants containing human vp7 remains to be determined. It should be noted that immunization of infants with bovine reassortant viruses containing both human outer capsid proteins vp4 and vp7 is probably less immunogenic than administration of bovine reassortants containing either human vp4 or vp7 (Clark et al., 1992). (3) Immunization with attenuated human rotaviruses: Perhaps replication at the mucosal surface induced by a human virus will induce protection against disease better than that induced by a primate rotavirus (RRV) also adapted to growth in the human intestine. However, trials of protective efficacy with human strain M37 were disappointing (Vesikari et al., 1991b). (4) Parenteral inoculation of inactivated rotaviruses or individual rotavirus proteins: Parenteral inoculation obviates concerns of inactivation of orally administered live virus by passively transferred maternal rotavirus-specific antibodies in milk (especially in developing countries) and by gastric acid, and may induce an immune response at the intestinal mucosal surface (e.g., virus-specific IgG) that is protective against challenge. (5) Oral or parenteral inoculation of rotavirus in a vehicle that allows for persistence of antigen (e.g., liposomes or micro-
capsules): This approach may prolong the normally short-lived sIgA response at the intestinal surface found after either natural infection or immunization.

References

Adams, W., and Kraft, L. (1967). Electron microscopic study of the intestinal epithelium of mice infected with the agent of epizootic diarrhea of infant mice (EDIM virus). Am. J. Pathol. 51, 39–44.

Ahmed, M., Urasawa, S., Taniguchi, K., Urasawa, T., Kobayashi, N., Wakasugi, F., Islam, A., and Sahikh, H. (1991). Analysis of human rotavirus strains prevailing in Bangladesh in relation to nationwide floods brought by the 1988 monsoon. J. Clin. Microbiol. 29, 2273–2279.

Aiyar, J., Ban, M., Bhandari, N., Kumar, R., Raj, P., and Sazawal, S. (1990). Rotavirus-specific antibody response in saliva of infants with rotavirus diarrhea. J. Infect. Dis. 162, 1383–1384.

Anderson, E., Belshe, R., Bartram, J., Crookshanks-Newman, F., Chanock, R., and Kapikian, A. (1986). Evaluation of rhesus rotavirus vaccine (MMU 18006) in infants and young children. J. Infect. Dis. 153, 823–839.

Andrew, M., Boyle, D., Whitfeld, P., Lockett, L., Anthony, I., Bellamy, A., and Both, G. (1990). The immunogenicity of vp7, a rotavirus antigen resident in the endoplasmic reticulum, is enhanced by cell surface expression. J. Virol. 64, 4776–4783.

Bellamy, A., and Both, G. (1990). Molecular biology of rotaviruses. Adv. Virus Res. 38, 1–43.

Bernstein, D., Sander, D., Smith, V., Schiff, G., and Ward, R. (1990a). Protection from rotavirus reinfection: 2-year prospective study. J. Infect. Dis. 164, 277–283.

Bernstein, D., Smith, V., Sander, D., Pax, K., Schiff, G., and Ward, R. (1990b). Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J. Infect. Dis. 162, 1055–1062.

Bingnan, F., Unicomb, L., Rahim, Z., Banu, N., Podder, G., Clemens, J., van Loon, F., Rao, M., Malek, A., and Tzipori, S. (1991). Rotavirus-associated diarrhea in rural Bangladesh: Two-year study of incidence and serotype distribution. J. Clin. Microbiol. 29, 1359–1363.

Bishop, R., Davidson, G., Holmes, I., and Ruck, B. (1973). Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet ii, 1281–1283.

Bishop, R., Barnes, G., Cipriani, E., and Lund, J. (1983). Clinical immunity after neo-
tal rotavirus infection: A prospective longitudinal study in young children. *N. Engl. J. Med.* 309, 72–76.

Bishop, R., Lund, J., Cipriani, E., Unicomb, L., and Barnes, G. (1990). Clinical, serological and intestinal immune responses to rotavirus infections in humans. In "Medical Virology" (L. de la Maza and E. Peterson, eds.), pp. 85–110. Plenum, New York.

Bishop, R., Unicomb, L., and Barnes, G. (1991). Epidemiology of rotavirus serotypes in Melbourne, Australia, from 1973 to 1989. *J. Clin. Microbiol.* 29, 862–868.

Black, R., Greenberg, H., Kapikian, A., Brown, K., and Becker, S. (1982). Acquisition of serum antibody to Norwalk virus and rotavirus in relation to diarrhea in a longitudinal study of young children in rural Bangladesh. *J. Infect. Dis.* 145, 483–489.

Blake, P., Ramos, S., MacDonald, K., Rassi, V., Gomes, A., Ivey, C., Bean, N., and Trabulsi, L. (1993). Pathogen-specific risk factors and protective factors for acute diarrheal disease in urban Brazilian infants. *J. Infect. Dis.* 167, 627–632.

Bohl, E., Theil, K., and Saif, L. (1984). Isolation and serotyping of porcine rotaviruses and antigenic comparison with other rotaviruses. *J. Clin. Microbiol.* 19, 105–111.

Both, G., Lockett, L., Janardhana, V., Edwards, S., Bellamy, A., Graham, F., Prevec, L., and Andrew, M. (1993). Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus vp7sc. *Virology* 193, 940–950.

Both, G., Bellamy, A., and Mitchell, D. (1994). Rotavirus protein structure and function. *Curr. Top. Microbiol. Immunol.* (in press).

Bridger, J., and Oldham, G. (1987). A virulent rotavirus infections protect calves from disease with and without inducing high levels of neutralizing antibodies. *J. Gen. Virol.* 68, 2311–2317.

Bridger, J., Oldham, G., Howard, C., and Parsons, K. (1992). In vivo depletion of CD8+ but not CD4+ or BOWC1+ lymphocytes increases primary rotavirus excretion in calves. *Int. Symp. Double-Stranded RNA Viruses, 4th, Scottsdale, Ariz. Abstr.*, S6–7.

Brussow, H., Offit, P., Gerna, G., Bruttin, A., and Sidoti, J. (1990). Polypeptide specificity of antiviral serum antibodies in children naturally infected with human rotavirus. *J. Virol.* 64, 4130–4136.

Buller, C., and Moxley, R. (1988). Natural infection of porcine ileal dome M cells with rotavirus and enteric adenovirus. *Vet. Pathol.* 25, 516–517.

Burns, J., Vo, P., Krishnaney, A., and Greenberg, H. (1992). Characterization of murine rotaviruses using the mouse model of rotavirus infection. *Int. Symp. Double-Stranded RNA Viruses, 4th, Scottsdale, Ariz. Abstr.*, S5–9.

Cerf-Bensussan, N., Guy-Grand, D., and Griscelli, C. (1985). Intraepithelial lymphocytes of the human gut: Isolation, characterization and study of natural killer activity. *Gut* 26, 81–88.

Chen, D., Estes, M., and Ramig, R. (1992). Specific interactions between rotavirus outer capsid proteins vp4 and vp7 determine expression of a cross-reactive, neutralizing vp4-specific epitope. *J. Virol.* 66, 432–439.

Chiba, S., Nakata, S., Urasawa, T., Urasawa, S., Yokoyama, T., Morita, Y., Taniguchi, K., and Nakao, T. (1986). Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. *Lancet* i, 417–421.

Christy, C., Madore, P., Pichichero, M., Gala, C., Pincus, P., Vosefski, D., Hoshino, Y., Kapikian, A., and Dolin, R. (1988). Field trials of rhesus rotavirus vaccine in infants. *Pediatr. Infect. Dis. J.* 7, 645–650.

Chrystile, I., Totterdell, B., and Banatvala, J. (1978). Asymptomatic endemic rotavirus infections in the newborn. *Lancet* i, 1176–1178.

Clark, H., Dolan, K., Horton-Slight, P., Palmer, J., and Plotkin, S. (1985). Diverse serologic response to rotavirus infection of infants in a single epidemic. *Pediatr. Infect. Dis. J.* 4, 626–631.
Clark, H., Furukawa, T., Bell, L., Offit, P., Parrella, P., and Plotkin, S. (1986). Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Am. J. Dis. Child. 140, 350–356.

Clark, H., Borian, F., Bell, L., Modesto, K., Gouvea, V., and Plotkin, S. (1988). Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J. Infect. Dis. 158, 570–587.

Clark, H., Borian, F., and Plotkin, S. (1990). Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3. J. Infect. Dis. 161, 1099–1104.

Clark, H., Welsko, D., and Offit, P. (1992). Infant responses to bovine rotavirus WC3 reassortants containing human rotavirus vp7, vp4 or vp7 + vp4. Int. Conf. Antimicrob. Agents Chemother., Anaheim, Calif., 343.

Clemens, J., Ward, R., Rao, M., Sack, D., Knowlton, D., van Loon, F., Huda, S., McNeal, M., Ahmed, F., and Schif, G. (1992). Seroepidemiologic evaluation of antibodies to rotavirus as correlates of the risk of clinically significant rotavirus diarrhea in rural Bangladesh. J. Infect. Dis. 165, 161–165.

Conner, M., Estes, M., and Graham, D. (1988). Rabbit model of rotavirus infection. J. Virol. 62, 1625–1633.

Conner, M., Gilger, M., Estes, M., and Graham, D. (1991). Serologic and mucosal immune response to rotavirus infection in the rabbit model. J. Virol. 65, 2562–2571.

Courthier, G., and Vannier, P. (1983). Production of coproantibodies and immune complexes in piglets infected with rotavirus. J. Infect. Dis. 147, 293–296.

Courthier, G., Vannier, P., (1983). Production of coproantibodies and immune complexes in piglets infected with rotavirus. J. Infect. Dis. 147, 293–296.

Coulson, B., Grimwood, K., Masendycz, P., Lund, J., Mermelstein, N., Bishop, R., and Barnes, G. (1990). Comparison of rotavirus immunoglobulin A coproconversion with other indices of rotavirus infection in a longitudinal study in childhood. J. Clin. Microbiol. 28, 1367–1374.

Coulson, B., Grimwood, K., Hudson, I., Barnes, G., and Bishop, R. (1992). Role of coproantibody in clinical protection of children during reinfection with rotavirus. J. Clin. Microbiol. 30, 1678–1684.

Crawford, S., Conner, M., Barone, C., Cohen, J., and Estes, M. (1992). Characterization of rotavirus subunit vaccine produced in insect cells. Int. Symp. Double-Stranded RNA Viruses, 4th, Scottsdale, Ariz. Abstr., 57–4.

Cukor, G., Blacklow, N., Capozza, F., Panjvani, Z., and Bednarek, F. (1979). Persistence of antibodies to rotavirus in human milk. J. Clin. Microbiol. 9, 93–96.

Cushing, A., and Anderson, L. (1982). Diarrhea in breast-fed and non-breast-fed infants. Pediatrics 70, 921–925.

Czerkinsky, C., Prince, S., Michalek, S., Jackson, S., Russell, M., Moldoveanu, Z., McGhee, J., and Mestecky, J. (1987). IgA antibody-producing cells in peripheral blood after antigen ingestion: Evidence for a common mucosal immune system in humans. Proc. Natl. Acad. Sci. U.S.A. 84, 2449–2453.

Dagan, R., Kassis, I., Sarov, B., Midthisn, K., Davidson, B., Vesikari, T., and Sarov, I. (1992). Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates. Pediatr. Infect. Dis. J. 11, 991–996.

Davidson, G., Goller, J., Bishop, R., Townley, R., Holmes, I., and Ruck, B. (1975). Immunofluorescence in duodenal mucosal of children with acute enteritis due to a new virus. J. Clin. Pathol. 28, 263–266.

Davidson, G., Hogg, R., and Kirubakaran, C. (1983). Serum and intestinal immune response to rotavirus enteritis in children. Infect. Immun. 40, 447–452.

Davidson, G., Daniels, E., Nunan, H., Moore, A., Whyte, P., Franklin, K., McCloud, P., and Moore, D. (1989). Passive immunization of children with bovine colostrum containing antibodies to human rotavirus. Lancet i, 709–712.

De Champs, C., Laveran, H., Peigue-Lahevile, H., Chambon, M., Demeocq, F., Gaulme,
PAUL A. OFFIT

J., and Beytout, D. (1991). Sequential rotavirus infections: Characterization of serotypes and electropherotypes. *Res. Virol.* 142, 39–45.

DeMol, P., Zissis, G., Butzler, J., Mutwewingsabo, A., and Andre, F. (1986). Failure of live, attenuated oral rotavirus vaccine. *Lancet* i, 108.

Dharakul, T., Riepenhoff-Talty, M., Albini, B., and Ogra, P. L. (1988). Distribution of rotavirus antigen in intestinal lymphoid tissues: Potential role in development of the mucosal immune response to rotavirus. *Clin. Exp. Immunol.* 74, 14–19.

Dharakul, T., Rott, L., and Greenberg, H. (1990). Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: Virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes. *J. Virol.* 64, 4375–4382.

Dharakul, T., Labbe, M., Cohen, J., Bellamy, A., Street, J., Mackow, E., Flore, L., Rott, L., and Greenberg, H. (1991). Immunization with baculovirus-expressed recombinant rotavirus proteins vp1, vp4, vp6, and vp7 induces CD8+ T lymphocytes that mediate clearance of chronic rotavirus infection in SCID mice. *J. Virol.* 65, 5928–5932.

Dormitzer, P., Ho, D., Mackow, E., Mocarski, E., and Greenberg, H. (1992). Neutralizing epitopes on herpes simplex-1-expressed rotavirus vp7 are dependent on coexpression of other rotavirus proteins. *Virology* 187, 18–32.

Duffy, L., Byers, T., Riepenhoff-Talty, La Scolea, L., Zielezny, M., and Ogra, P. (1986a). The effects of infant feeding on rotavirus-induced gastroenteritis: A prospective study. *Am. J. Public Health* 76, 259–263.

Duffy, L., Riepenhoff-Talty, M., Byers, T., La Scolea, L., Zielezny, M., Dryja, D., and Ogra, P. (1986b). Modulation of rotavirus enteritis during breast-feeding. *Am. J. Dis. Child.* 140, 1164–1168.

Estes, M., and Cohen, J. (1989). Rotavirus gene structure and function. *Microbiol. Rev.* 53, 410–449.

Estes, M., Palmer, E., and Obijeski, J. (1983). Rotaviruses: A review. *Curr. Top. Microbiol. Immunol.* 105, 123–184.

Evavold, B., and Allen, P. (1991). Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. *Science* 252, 1308–1310.

Faden, H., Modlin, J., Thoms, M., McBean, A., Ferdon, M., and Ogra, P. (1990). Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses. *J. Infect. Dis.* 162, 1291–1297.

Flores, J., Gonzalez, M., Perez, M., Cunto, W., Perez-Schael, I., Garcia, D., Daoud, N., Chanock, R., and Kapikian, A. (1987). Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. *Lancet* i, 882–884.

Flores, J., Taniguchi, K., Green, K., Perez-Schael, I., Garcia, D., Sears, J., Urasawa, S., and Kapikian, A. (1988). Relative frequencies of rotavirus serotypes 1, 2, 3, and 4 in Venezuelan infants with gastroenteritis. *J. Clin. Microbiol.* 26, 2092–2095.

Flores, J., Perez-Schael, I., Blanco, M., Vilar, M., Garcia, D., Perez, M., Daoud, N., Midthun, K., and Kapikian, A. (1989). Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants. *J. Clin. Microbiol.* 27, 512–518.

Franco, M., Prieto, I., Labbe, M., Poncet, D., Borras-Cuesta, F., and Cohen, J. (1992). Identification of cytotoxic T cell epitopes on the vp7 rotaviral protein. *Int. Symp. Double-Stranded RNA Viruses, 4th, Scottsdale, Ariz.* Abstr., S6–8.

Friedman, M., Gaul, A., Sarov, B., Margalith, M., Katzir, G., Midthun, K., Taniguchi, K., Urasawa, S., Kapikian, A., Edelman, R., and Sarov, I. (1988). Two sequential outbreaks of rotavirus gastroenteritis: evidence for symptomatic and asymptomatic reinfection. *J. Infect. Dis.* 158, 814–822.

Fuhrman, J., and Cebra, J. (1981). Special features of the priming process for secretory IgA response: B cell priming with cholera toxin. *J. Exp. Med.* 153, 534–544.
Gaul, S., Simpson, T., Woode, G., and Fulton, R. (1982). Antigenic relationships among some animals rotaviruses: Virus neutralization in vitro and cross-protection in piglets. *J. Clin. Microbiol.* 16, 495–503.

Gentsch, J., Glass, R., Woods, P., Gouvea, V., Gorziglia, M., Flores, J., Das, B., and Bhan, M. (1992). Identification of group A rotavirus gene 4 types by polymerase chain reaction. *J. Clin. Microbiol.* 30, 1365–1373.

Georges-Courbot, M., Monges, J., Beraud-Cassel, A., Gouandika, I., and Georges, A. (1988). Prospective longitudinal study of rotavirus infections in children from birth to two years of age in Central Africa. *Ann. Inst. Pasteur/Virol.* 139, 421–428.

Georges-Courbot, M., Monges, J., Siopathis, M., Roungou, J., Gresenguet, G., Bellec, L., Bouquet, J., Lanckriet, C., Cadoz, M., Hessel, L., Gouvea, V., Clark, F., and Georges, A. (1991). Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. *Res. Virol.* 142, 405–411.

Gerna, G., Sarasini, Z., Torsellini, M., Torre, D., Parea, M., and Battaglia, M. (1990). Group- and type-specific serologic response in infants and children with primary rotavirus infections and gastroenteritis caused by a strain of known serotype. *J. Infect. Dis.* 161, 1105–1111.

Glass, R., Svennerholm, A., Stoll, B., Khan, M., Hossain, K., Huq, I., and Holmgren, J. (1983). Protection against cholera in breast-fed children by antibodies in breast milk. *N. Engl. J. Med.* 308, 1389–1392.

Glass, R., Stoll, B., Wyatt, R., Hoshino, Y., Banu, H., and Kapikian, A. (1986). Observations questioning a protective role for breast-feeding in severe rotavirus diarrhea. *Acta Pediatr. Scand.* 75, 713–718.

Goldblum, R., Ahlstedt, S., Carlsson, B., Hanson, L., Jodal, V., Lider-Janson, G., and Sohl-Akerlund, A. (1975). Antibody-forming cells in human colostrum after oral immunization. *Nature (London)* 257, 797–799.

Gorziglia, M., Larralde, G., Kapikian, A., and Chanock, R. (1990). Antigenic relationships among human rotaviruses as determined by outer capsid protein vp4. *Proc. Natl. Acad. Sci. U.S.A.* 87, 7155–7159.

Gothefors, L., Wadell, G., Juto, P., Taniguchi, K., Kapikian, A., and Glass, R. (1990). Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. *J. Infect. Dis.* 159, 753–757.

Green, K., and Kapikian, A. (1992). Identification of vp7 epitopes associated with protection against human rotavirus illness or shedding in volunteers. *J. Virol.* 66, 548–553.

Green, K., Taniguchi, K., Mackow, E., and Kapikian, A. (1990). Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccines: Implications for vaccine development. *J. Infect. Dis.* 161, 667–679.

Greenberg, H., Vo, P., and Jones, R. (1986). Cultivation and characterization of three strains of murine rotavirus. *J. Virol.* 57, 585–590.

Greenberg, H., Clark, F., and Offit, P. (1993). Rotavirus pathology and pathophysiology. *Curr. Top. Microbiol. Immunol.* (in press).

Grimwood, K., Lund, J., Coulson, B., Hudson, I., Bishop, R., and Barnes, G. (1988). Comparison of serum and mucosal antibody responses following severe acute rotavirus gastroenteritis in young children. *J. Clin. Microbiol.* 26, 732–738.

Grinstein, S., Gomez, J., Bercovich, J., and Biscon, E. (1989). Epidemiology of rotavirus infection and gastroenteritis in prospectively monitored Argentine families with young children. *Am. J. Epidemiol.* 130, 300–308.

Grunow, J., Dunton, S., and Waner, J. (1985). Human rotavirus-like particles in a hepatic abscess. *J. Pediatr.* 106, 73–76.

Guarino, A., Guandalini, S., Albano, F., Mascia, A., Ritis, G., and Rubino, A. (1991). Enteral immunoglobulins for treatment of protracted rotaviral diarrhea. *Pediatr. Infect. Dis. J.* 10, 612–614.
Guy-Grand, D., Griscelli, C., and Vassali, P. (1978). The mouse gut T lymphocyte, a novel type of cell: Nature, origin, and traffic in mice in normal and graft-versus-host conditions. *J. Exp. Med.* 148, 1661–1677.

Hamabraeus, A., Hamabraeus, L., and Wadell, G. (1989). Animal model of rotavirus infection in rabbits—protection obtained without shedding of viral antigen. *Arch. Virol.* 107, 237–251.

Hanlon, P., Marsh, V., Shenton, F., Jobe, O., Hayes, R., Whittle, H., Hanlon, L., Byass, P., Hassan-King, M., Sillah, H., m'Boge, B., and Greenwood, B. (1987). Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. *Lancet* i, 1342–1345.

Hattori, H., Torii, S., Nagafuji, H., Tabata, Y., and Hata, A. (1992). Benign acute myositis associated with rotavirus gastroenteritis. *J. Pediatr.* 121, 748–749.

Haug, K., Orstavik, I., and Kvelstad, G. (1978). Rotavirus infections in families: A clinical and virological study. *Scand. J. Infect. Dis.* 10, 265–269.

Hilpert, H., Brussow, H., Mietens, C., Sidoti, J., Lerner, L., and Werchau, H. (1987). Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. *J. Infect. Dis.* 158, 158–165.

Ho, M., Glass, R., Pinsky, P., and Anderson, L. (1988a). Rotavirus as a cause of diarrheal morbidity and mortality in the U.S. *J. Infect. Dis.* 158, 1112–1116.

Ho, M., Glass, R., Pinsky, P., Young-Okoh, N., Sappenfield, W., Buehler, J., Gunter, N., and Anderson, L. (1988b). Diarrheal diseases in American children: Are they preventable? *J. Am. Med. Assoc.* 260, 3281–3285.

Hoshino, Y., Sereno, M., Midthun, K., Flores, J., Kapikian, A., and Chanock, R. (1985). Independent segregation of two antigenic specificities (vp3 and vp7) involved in neutralization of rotavirus infectivity. *Proc. Natl. Acad. Sci. U.S.A.* 82, 8701–8704.

Hoshino, Y., Saif, L., Sereno, M., Chanock, R., and Kapikian, A. (1988). Infection immunity of piglets to either vp3 or vp7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen. *J. Virol.* 62, 744–748.

Hlaz, M., Attah-Poku, S., Redmund, M., Parker, M., Sabara, M., and Babik, L. (1991). Heterotypic passive protection induced by synthetic peptides corresponding to vp7 and vp4 of bovine rotavirus. *J. Virol.* 65, 3106–3113.

Jayashree, S., Bhan, M., Raj, P., Kumar, R., Svennson, L., Stintzing, G., and Bhandari, N. (1988). Neonatal rotavirus infection and its relation to cord blood antibodies. *Scand. J. Infect. Dis.* 20, 249–253.

Kapikian, A., Kim, H., Wyatt, R., Cline, W., Arrobio, J., Brandt, C., Rodriguez, W., Sack, D., Chanock, R., and Parrott, R. (1976). Human reovirus-like agent as the major pathogen associated with “winter” gastroenteritis in hospitalized infants and young children. *N. Engl. J. Med.* 294, 965–972.

Kapikian, A., Wyatt, R., Levine, M., Yolken, R., Vankirk, D., Dolin, R., Greenberg, H., and Chanock, R. (1983). Oral administration of human rotavirus to volunteers: Induction of illness and correlates of resistance. *J. Infect. Dis.* 147, 95–106.

Kim, H., Brandt, C., Kapikian, A., Wyatt, R., Arrobio, J., Rodriguez, W., Chanock, R., and Parrott, R. (1977). Human reovirus-like agent infection; occurrence in adult contacts of pediatric patients with gastroenteritis. *J. Am. Med. Assoc.* 238, 404–407.

Kitaoaka, S., Fukuhara, N., Tazawa, F., Suzuki, H., Sato, T., Konno, T., Ebina, T., and Ishida, N. (1986). Characterization of monoclonal antibodies against human rotavirus hemagglutinin. *J. Med. Virol.* 19, 313–323.

Lanata, C., Black, R., del Aguila, R., Gil, A., Verastegui, H., Gerna, G., Flores, S., Kapikian, A., and Andre, P. (1989). Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. *J. Infect. Dis.* 169, 452–459.

LeBaron, C., Lew, J., Glass, R., Weber, J., and Ruiz-Palacios, G. (1990). Rotavirus Study
Group. Annual rotavirus epidemic patterns in North America. *J. Am. Med. Assoc.* 264, 983–988.

Lecce, J., Leary, H., Clare, D., and Batema, R. (1991). Protection of agammaglobulinemic piglets from porcine rotavirus infection by antibody against simian rotavirus SA-11. *J. Clin. Microbiol.* 29, 1382–1386.

Linares, A., Gabbay, Y., Mascarenhas, J., Freitas, R., Flewett, T., and Beards, G. (1988). Epidemiology of rotavirus subgroups and serotypes in Belem, Brazil: A three-year study. *Ann. Inst. Pasteur/Virol.* 139, 89–99.

Losonsky, G., and Reymann, M. (1990). The immune response in primary asymptomatic and symptomatic rotavirus infection in newborn infants. *J. Infect. Dis.* 161, 330–332.

Losonsky, G., Vonderfecht, S., Eiden, J., Wee, S., and Yolken, R. (1986a). Homotypic and heterotypic antibodies for prevention of experimental rotavirus gastroenteritis. *J. Clin. Microbiol.* 24, 1041–1044.

Losonsky, G., Rennels, M., Kapikian, A., Midthun, K., Ferra, P., Fortier, D., Hoffman, K., Baig, A., and Levine, M. (1986b). Safety, infectivity, transmissibility and immunogenicity of rhesus rotavirus vaccine (MMU 18006) in infants. *Pediatr. Infect. Dis. J.* 5, 25–29.

Losonsky, G., Rennels, M., Lim, Y., Krall, G., Kapikian, A., and Levine, M. (1988). Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006. *Pediatr. Infect. Dis. J.* 7, 388–393.

Mackow, E., Shaw, R., Matsui, S., Vo, P., Dang, M., and Greenberg, H. (1988). The rhesus rotavirus gene encoding vp3; location of amino acids involved in homologous and heterologous rotavirus neutralization and identification of a putative fusion region. *Proc. Natl. Acad. Sci. U.S.A.* 85, 645–649.

Matson, D., Estes, M., Burns, J., Greenberg, H., Taniguchi, K., and Urasawa, S. (1990). Serotype variation of human group A rotaviruses in two regions of the USA. *J. Infect. Dis.* 162, 605–614.

Matsui, S., Mackow, E., and Greenberg, H. (1989a). Molecular determinant of rotavirus neutralization and protection. *Adv. Virus Res.* 36, 181–214.

Matsui, S., Offit, P., Vo, P., Mackow, E., Benfield, D., Shaw, R., Padilla-Noriega, L., and
Greenberg, H. (1989b). Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of vp7 and the vp8 fragment of vp4. *J. Clin. Microbiol.* 27, 780–782.

Matsuno, S., Utagawa, E., and Sugiura, A. (1983). Association of rotavirus infection with Kawasaki syndrome. *J. Infect. Dis.* 148, 177.

Mattion, N., Mitchell, D., Both, G., and Estes, M. (1991). Expression of rotavirus proteins encoded by alternative open reading frames of genome segment 11. *Virology* 181, 295–304.

McNeal, M., Sheridan, J., and Ward, R. (1992). Active protection against rotavirus infection of mice following intraperitoneal immunization. *Virology* 191, 150–157.

Mebus, C. (1976). Reovirus-like calf enteritis. *Dig. Dis. Sci.* 21, 592–598.

Mebus, C., White, R., Bass, E., and 'nviehaus, M. (1973). Immunity to neonatal calf diarrhea virus. *J. Am. Vet. Med. Assoc.* 163, 880–883.

Merchant, A., Groene, W., Cheng, E., and Shaw, R. (1991). Murine intestinal antibody response to heterologous rotavirus infection. *J. Clin. Microbiol.* 29, 1693–1701.

Midthun, K., Greenberg, H., Hoshino, Y., Kapikian, A., Wyatt, R., and Chanock, R., (1985). Reassortant rotaviruses as potential live rotavirus vaccine candidates. *J. Virol.* 53, 949–954.

Midthun, Hoshino, Y., Kapikian, A., and Chanock, R. (1986). Single gene substitution rotavirus reassortants containing the major neutralization protein (vp7) of human rotavirus serotype 4. *J. Clin. Microbiol.* 24, 822–826.

Midthun, K., Pang, L., Flores, J., and Kapikian, A. (1989). Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque-reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates. *J. Clin. Microbiol.* 27, 2799–2804.

Midthun, K., Halsey, N., Jett-Goheen, M., Clements, M., Steinhoff, M., King, J., Karron, R., Wilson, M., Burns, B., Perkis, V., Samorodin, R., and Kapikian, A. (1991). Safety and immunogenicity of human rotavirus vaccine strain M37 in adults, children, and infants. *J. Infect. Dis.* 164, 792–796.

Nishikawa, K., Fukuhara, N., Liprandi, F., Green, K., Kapikian, A., Chanock, R., and Gorziglia, M. (1989). Vp4 protein of porcine rotavirus strain OSU expressed by a baculovirus recombinant induces neutralizing antibodies. *Virology* 173, 631–637.

Noel, J., Beards, G., and Cubitt, W. (1991). Epidemiological survey of human rotavirus serotypes and electropherotypes in young children admitted to two children's hospitals in northeast London from 1984 to 1990. *J. Clin. Microbiol.* 29, 2213–2219.

Offit, P., and Blavat, G. (1986). Identification of the two rotavirus genes determining neutralization specificities. *J. Virol.* 57, 376–378.

Offit, P., and Clark, H. (1985a). Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies. *J. Virol.* 54, 58–64.

Offit, P., and Clark, H. (1985b). Maternal antibody-mediated protection against gastroenteritis due to rotavirus in newborn mice is dependent on both serotype and titer of antibody. *J. Infect. Dis.* 162, 1152–1158.

Offit, P., and Dudzik, K. (1988). Rotavirus-specific cytotoxic T lymphocytes cross-react with target cells infected with different rotavirus serotypes. *J. Virol.* 62, 127–131.

Offit, P., and Dudzik, K. (1989a). Noninfectious rotavirus (strain RRV) induces an immune response in mice which protects against rotavirus challenge. *J. Clin. Microbiol.* 27, 885–888.

Offit, P., and Dudzik K. (1989b). Rotavirus-specific cytotoxic T lymphocytes appear at the intestinal mucosal surface after rotavirus infection. *J. Virol.* 63, 3507–3512.

Offit, P., and Dudzik, K. (1990). Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice. *J. Virol.* 64, 6325–6328.
Offit, P., Clark, H., Kornstein, M., and Plotkin, S. (1984). A murine model for oral infection with a primate rotavirus (simian SA11). *J. Virol.* 51, 233–236.

Offit, P., Clark, H., Blavat, G., and Greenberg, H. (1986a). Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype. *J. Virol.* 60, 491–496.

Offit, P., Shaw, R., and Greenberg, H. (1986b). Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7. *J. Virol.* 58, 700–703.

Offit, P., Cunningham, S., and Dudzik, K. (1991a). Memory and distribution of virus-specific cytotoxic T lymphocytes (CTLs) and CTL precursors after rotavirus infection. *J. Virol.* 65, 1318–1324.

Offit, P., Boyle, D., Both, G., Hill, N., Svoboda, Y., Cunningham, S., Jenkins, R., and McRae, M. (1991b). Outer capsid glycoprotein vp7 is recognized by cross-reactive, rotavirus-specific, cytotoxic T lymphocytes. *Virology* 184, 563–568.

Offit, P., Hoffenberg, E., Santos, N., and Gouvea, V. (1993). Rotavirus-specific humoral and cellular immune response after primary, symptomatic infection. *J. Infect. Dis.* 167, 1436–1440.

Offit, P., Coupar, B., Suoboda, J., Jenkins, R., McRae, M., Abraham, A., Hill, N., Boyle, P., Andrew, M., and Both, G. (1994). Induction of rotavirus-specific cytotoxic T lymphocytes by vaccinia virus recombinants expressing individual rotavirus genes. *Virology* 198, 10–16.

Onraeto, I., Modlin, J., McBean, A., Thomas, M., Losonsky, G., and Bernier, R. (1991). Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. *J. Infect. Dis.* 163, 1–6.

O’Ryan, M., Matson, D., Estes, M., Bartlett, A., and Pickering, L. (1990). Molecular epidemiology of rotavirus in young children attending day care centers in Houston. *J. Infect. Dis.* 162, 810–816.

Otnaess, A., and Orstavik, I. (1980). The effect of human milk fractions on rotavirus in relation to the secretory IgA content. *Acta Pathol. Microbiol. Scand.* 88, 15–21.

Padilla-Noriega, L., Arias, C., Lopez, S., Puerto, F., Snodgrass, D., Taniguchi, K., and Greenberg, H. (1990). Diversity of rotavirus serotypes in Mexican infants with gastroenteritis. *J. Clin. Microbiol.* 28, 1114–1119.

Padilla-Noriega, L., Fiore, L., Rennels, M., Losonsky, G., Mackow, E., and Greenberg, H. (1992). Humoral immune responses to vp4 and its cleavage products vp5* and vp8* in infants vaccinated with rhesus rotavirus. *J. Clin. Microbiol.* 30, 1392–1397.

Perez-Schael, I., Daoud, G., White, L., Urbina, G., Daoud, N., Perez, M., and Flores, J. (1984). Rotavirus shedding by newborn children. *J. Med. Virol.* 14, 127–136.

Perez-Schael, I., Gonzalez, M., Daoud, N., Perez, M., Soto, I., Garcia, D., Daoud, G., Kapikian, A., and Flores, J. (1987). Reactogenicity and antigenicity of the rhesus rotavirus vaccine in Venezuelan children. *J. Infect. Dis.* 155, 334–338.

Perez-Schael, I., Garcia, D., Gonzalez, M., Gonzalez, R., Daoud, N., Perez, M., Cunot, W., Kapikian, A., and Flores, J. (1990a). Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. *J. Med. Virol.* 30, 219–229.

Perez-Schael, I., Blanco, M., Vilar, M., Garcia, D., White, L., Gonzalez, R., Kapikian, A., and Flores, J. (1990b). Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. *J. Clin. Microbiol.* 28, 553–558.

Petit, A., Ernst, P., Befus, A., Clark, D., Rosenthal, K., Ishizaka, T., and Bienenstock, J. (1985). Murine intestinal epithelial lymphocytes. I. Relationship of a novel Thy1−, Lyt1−, Lyt2+ granulated subpopulation to natural killer cells and mast cells. *Eur. J. Immunol.* 15, 211–215.

Puerto, F., Padilla-Noriega, L., Zamora-Chavez, A., Briceno, A., Puerto, M., and Arias,
C. (1987). Prevalent patterns of serotype-specific seroconversion in Mexican children infected with rotavirus. *J. Clin. Microbiol.* **25**, 960–963.

Quiding, M., Nordstrom, I., Kilander, A., Andersson, G., Hanson, L., Holmgren, J., and Czerkinsky, C. (1991). Intestinal immune response in humans: Oral cholera vaccination induces strong intestinal antibody responses and interferon-γ production and evokes local immunological memory. *J. Clin. Invest.* **88**, 143–148.

Redmond, M., Ijaz, M., Parker, M., Sabara, M., Dent, D., Gibbons, E., and Babiuk, L. (1993). Assembly of recombinant rotavirus proteins into virus-like particles and assessment of vaccine potential. *Vaccine* **11**, 273–281.

Rennels, M., Losonsky, G., Levine, M., Kapikian, A., and the Clinical Study Group (1986). Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children. *Pediatr. Infect. Dis. J.* **5**, 587–588.

Rennels, M., Losonsky, G., Shindledecker, C., Hughes, T., Kapikian, A., Levine, M., and the Clinical Study Group. (1987). Immunogenicity and reactogenicity of lowered doses of rhesus rotavirus vaccine strain MMU 18006 in young children. *Pediatr. Infect. Dis. J.* **6**, 260–264.

Rennels, M., Losonsky, G., Young, A., Shindledecker, C., Kapikian, A., Levine, M., and the Clinical Study Group. (1990). An efficacy trial of the rhesus rotavirus vaccine in Maryland. *Am. J. Dis. Child.* **144**, 601–604.

Reves, R., Hossain, M., Midthun, K., Kapikian, A., Naguib, T., Zaki, A., and Dupont, H. (1989). An observational study of naturally-acquired immunity to rotavirus diarrhea in a cohort of 363 Egyptian children. *Am. J. Epidemiol.* **130**, 981–988.

Riepenhoff-Talty, M., Bogger-Goren, S., Li, P., Carmody, P., Barrett, H., and Ogra, P. (1981). Development of serum and intestinal antibody response to rotavirus after naturally acquired rotavirus infection in man. *J. Med. Virol.* **8**, 215–222.

Riesen, W., and Offit, P. (1992). Intestinal rotavirus-specific helper T cell response in mice after acute infection. *Int. Symp. Double-Stranded RNA Viruses, 4th, Scottsdale, Ariz.* Abstr., 31.

Ringenbergs, M., Albert, M., Davidson, G., Goldsworthy, W., and Haslam, R. (1988). Serotype-specific antibodies to rotavirus in human colostrum and breast milk and in maternal and cord blood. *J. Infect. Dis.* **158**, 477–480.

Rodriguez, W., Kim, H., Arrobio, J., Brandt, C., Chanock, R., Kapikian, A., Wyatt, R., and Parrot, R. (1977). Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children. *J. Pediatr.* **91**, 188–193.

Rodriguez, W., Kim, H., Brandt, C., Yolken, R., Richard, M., Arrobio, J., Schwartz, R., Kapikian, A., Chanock, R., and Parrott, R. (1979). Common exposure outbreak of gastroenteritis due to type 2 rotavirus with high secondary attack rate within families. *J. Infect. Dis.* **140**, 353–357.

Rodriguez, W., Kim, H., Brandt, C., Schwartz, R., Gardner, M., Jeffries, B., Parrott, R., Kaslow, R., Smith, J., and Kapikian, A. (1987). Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: Clinical and epidemiologic observations. *Pediatr. Infect. Dis. J.* **6**, 170–176.

Rotbart, H., Levin, M., Yolken, R., Manchester, D., and Jantzen, J. (1983). An outbreak of rotavirus-associated necrotizing enterocolitis. *J. Pediatr.* **103**, 454–459.

Rotbart, H., Nelson, W., Glade, M., Triffon, T., Kogut, S., Yolken, R., Hernandez, J., and Levin M. (1988). Neonatal rotavirus-associated necrotizing enterocolitis: Case control study and prospective surveillance during an outbreak. *J. Pediatr.* **112**, 87–93.

Ryder, R., Singh, N., Reeves, W., Kapikian, A., Greenberg, H., and Sack, R. (1985). Evidence of immunity induced by naturally acquired rotavirus and Norwalk virus infection on two remote Panamanian islands. *J. Infect. Dis.* **151**, 99–105.

Sack, D. (1992). Efficacy of rhesus rotavirus monovalent or tetravalent oral vaccines in US children. *Int. Conf. Antimicrob. Agents Chemother., Anaheim, Calif.* Abstr., 344.
Saif, L. (1987). Development of nasal, fecal, and serum isotype-specific antibodies in calves challenged with bovine coronavirus or rotavirus. *Vet Immunol. Immunopathol.* 17, 425-439.

Saif, L., Redman, D., Smith, K., and Theil, K. (1983). Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from immunized and unimmunized cows. *Infect. Immun.* 41, 1118-1131.

Saif, L., Chen, W., Campbell, T., and VanCott, J. (1992). Enumeration of antibody-secreting cells in the mucosal lymphoid tissues of pig inoculated with rotavirus. *Int. Symp. Double-Stranded RNA Viruses, 4th, Scottsdale, Ariz.* Abstr., 39.

Salmi, T., Arstila, P., and Koivikko, A. (1978). Central nervous system involvement in patients with rotavirus gastroenteritis. *Scand. J. Infect. Dis.* 10, 29-31.

Santosham, M., Yolken, R., Quiroz, E., Dillman, L., Oro, G., Reeves, W., and Sack, R. (1983). Detection of rotavirus in respiratory secretions of children with pneumonia. *J. Pediatr.* 103, 583-585.

Saulsbury, F., Winkelstein, J., and Yolken, R. (1980). Chronic rotavirus infection in immunodeficiency. *J. Pediatr.* 97, 61-65.

Schaller, J., Saif, L., Cordle, C., Cable, E., Winship, T., and Smith, K. (1992). Prevention of human rotavirus-induced diarrhea in gnotobiotic piglets using bovine antibody. *J. Infect. Dis.* 165, 623-630.

Shaw, R., Fong, K., Losonsky, G., Levine, M., Maldonado, Y., Yolken, R., Flores, J., Kapikian, A., Vo, P., and Greenberg, H. (1987). Epitope-specific immune responses to rotavirus vaccination. *Gastroenterology* 93, 941-950.

Shaw, R., Groene, W., Mackow, E., Merchant, A., and Cheng, E. (1991). Vp4-specific intestinal antibody response to rotavirus in a murine model of heterotypic protection. *J. Virol.* 65, 3052-3059.

Shaw, R., Merchant, A., Groene, W., and Cheng, E. (1993). Persistence of intestinal antibody response to heterologous rotavirus infection in a murine model beyond 1 year. *J. Clin. Microbiol.* 31, 188-191.

Sheridan, J., Eydelloth, R., Vonderfecht, S., and Aurelian, L. (1983). Virus-specific immunity in neonatal and adult mouse rotavirus infection. *Infect. Immun.* 39, 917-927.

Sheridan, J., Smith, C., Manak, M., and Aurelian, L. (1984). Prevention of rotavirus-induced diarrhea in neonatal mice born to dams immunized with empty capsids of simian rotavirus SA-11. *J. Infect. Dis.* 149, 434-438.

Snodgrass, D., and Wells, P. (1976). Rotavirus infections in lambs: Studies on passive protection. *Arch. Virol.* 52, 201-205.

Snodgrass, D., and Wells, P. (1978a). Passive immunity in rotaviral infections. *J. Am. Vet. Med. Assoc.* 173, 565-568.

Snodgrass, D., and Wells, P. (1978b). The immunoprophylaxis of rotavirus infections in lambs. *Vet. Rec.* 102, 146-148.

Snodgrass, D., Madeley, C., Wells, P., and Angus, K. (1977). Human rotavirus in lambs: Infection and passive protection. *Infect. Immun.* 16, 268-270.

Snodgrass, D., Fahey, K., Wells, P., Campbell, I., and Whitelaw, A. (1980). Passive immunity in calf rotavirus infections: Maternal vaccination increases and prolongs immunoglobulin G1 antibody secretion in milk. *Infect. Immun.* 28, 344-349.

Snyder, J., and Merson, M. (1982). The magnitude of the global problem of acute diarrhoeal disease: A review of active surveillance data. *Bull. W.H.O.* 60, 605-613.

Stoll, B., Glass, R., Hug, M., Khan, M., Banu, H., and Holt, J. (1982). Epidemiologic and clinical features of patients infected with shigella who attended a diarrhea disease hospital in Bangladesh. *J. Infect. Dis.* 146, 177-183.

Taniguchi, K., Maloy, W., Nishikawa, K., Green, K., Hoshino, Y., Urasawa, S., and Kapikian, A. (1988). Identification of cross-reactive and serotype 2-specific neutralization epitopes on vp3 of human rotavirus. *J. Virol.* 62, 2421-2426.
Totterdell, B., Chrystie, I., and Banatvala, J. (1980). Cord blood and breast-milk antibodies in neonatal rotavirus infection. Brit. Med. J. ii, 828–830.

Totterdell, B., Nicholson, K., MacLeod, J., Chrystie, I., and Banatvala, J. (1982). Neonatal rotavirus infection: Role of lacteal neutralising alpha1-anti-trypsin and non-immunoglobulin antiviral activity in protection. J. Med. Virol. 10, 37–44.

Urasawa, S., Urasawa, T., Taniguchi, K., and Chiba, S. (1984). Serotype determination of human rotavirus isolates and antibody prevalence of pediatric population in Hokkaido, Japan. Arch. Virol. 81, 1–12.

Vesikari, T., Isolauri, E., Delem, A., D’Hondt, E., Andre, F., and Zissis, G. (1983). Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet ii, 807–811.

Vesikari, T., Isolauri, E., D’Hondt, E., Delem, A., Andre, F., and Zissis, G. (1984). Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet i, 977–981.

Vesikari, T., Ruuska, T., Bogaerts, H., Delem, A., and Andre, F. (1985a). Dose-response study of RIT 4237 oral rotavirus vaccine in breast-fed and formula-fed infants. Pediatr. Infect. Dis. J. 4, 622–625.

Vesikari, T., Isolauri, E., Delem, A., D’Hondt, E., Andre, F., Beards, G., and Flewett, T. (1985b). Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J. Pediatr. 107, 189–194.

Vesikari, T., Ruuska, T., Delem, A., and Andre, F. (1986). Oral rotavirus vaccination in breast- and bottle-fed infants aged 6 to 12 months. Acta Paediatr. Scand. 75, 573–578.

Vesikari, T., Rautanen, T., Varis, T., Beards, G., and Kapikian, A. (1990). Rhesus rotavirus candidate vaccine: Clinical trial in children vaccinated between 2 and 5 months of age. Am. J. Dis. Child. 144, 285–289.

Vesikari, T., Ruuska, T., Delem, A., Andre, F., Beards, G., and Flewett, T. (1991a). Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Pediatr. Scand. 80, 173–180.

Vesikari, T., Ruuska, T., Koivu, H., Green, K., Flores, J., and Kapikian, A. (1991b). Evaluation of the M37 human rotavirus vaccine in 2- to 6-month-old infants. Pediatr. Infect. Dis. J. 10, 912–917.

Vesikari, T., Ruuska, T., Green, K., Flores, J., and Kapikian, A. (1992). Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus vp7 serotype 1 or 2 specificity. Pediatr. Infect. Dis. J. 11, 535–542.

Vonderfecht, S., and Osburn, B. (1982). Immunity to rotavirus in conventional neonatal calves. J. Clin. Microbiol. 16, 935–942.

Walsh, J., and Warren, K. (1979). Selective primary health care: An interim strategy for disease control in developing countries. N. Engl. J. Med. 301, 967–974.

Ward, R., Bernstein, D., Young, E., Sherwood, J., Knowlton, D., and Schiff, G. (1986). Human rotavirus studies in volunteers: Determination of infectious dose and serological response to infection. J. Infect. Dis. 154, 871–880.

Ward, R., Knowlton, D., Schiff, G., Hoshino, Y., and Greenberg, H. (1988). Relative concentrations of serum neutralizing antibody to vp3 and vp7 proteins in adults infected with a human rotavirus. J. Virol. 62, 1543–1549.

Ward, R., Bernstein, D., Shukla, R., Young, E., Sherwood, J., McNeal, M., Walker, M., and Schiff, G. (1989). Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J. Infect. Dis. 159, 79–88.

Ward, R., McNeal, M., and Sheridan, J. (1990). Development of an adult mouse model for studies of protection against rotavirus. J. Virol. 64, 5070–5075.

Ward, R., McNeal, M., and Sheridan, J. (1992a). Evidence that active protection follow-
ing oral immunization of mice with live rotavirus is not dependent on neutralizing antibody. *Virology* **188**, 57–66.

Ward, R., Clemens, J., Knowlton, D., Rao, M., van Loon, F., Huda, N., Ahmed, F., Schiff, G., and Sack, D. (1992b). Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. *J. Infect. Dis.* **166**, 1251–1257.

Ward, R., McNeal, M., Sander, D., Greenberg, H., and Bernstein, D. (1993). Immuno-dominance of the vp4 neutralization protein of rotavirus in protective natural infections of young children. *J. Virol.* **67**, 464–468.

Weinberg, R., Tipton, G., Klish, W., and Brown, M. (1984). Effect of breast-feeding on morbidity in rotavirus gastroenteritis. *Pediatrics* **74**, 250–253.

Whorwell, P., Beeken, W., Phillips, C., Little, P., and Roessner, K., (1977). Isolation of reovirus-like agents from patients with Crohn’s disease. *Lancet* i, 1169–1171.

Wong, C., Price, Z., and Bruckner, D. (1984). Aseptic meningitis in an infant with rotavirus gastroenteritis. *Pediatr. Infect. Dis. J.* **3**, 244–246.

Wood, D., David, T., Chrystie, I., and Totterdell, B. (1988). Chronic enteric virus infection in two T-cell immunodeficient children. *J. Med. Virol.* **24**, 435–444.

Woode, G., Jones, J., and Bridger, J. (1975). Levels of colostral antibodies against neonatal calf diarrhoea virus. *Vet. Rec.* **97**, 148–149.

Woode, G., Bew, M., and Dennis, M. (1978). Studies on cross protection induced in calves by rotavirus of calves, children and foals. *Vet. Rec.* **103**, 32–34.

Woode, G., Kelso, N., Simpson, T., Gaul, S., Evans, L., and Babiuk, L. (1983). Antigenic relationships among some bovine rotaviruses: Serum neutralization and cross-protection in gnotobiotic calves. *J. Clin. Microbiol.* **18**, 358–364.

Woode, G., Zheng, S., Rosen, B., Knight, N., Gourley, N., and Ramig, R. (1987). Protection between different serotypes of bovine rotavirus in gnotobiotic calves: Specificity of serum antibody and coproantibody responses. *J. Clin. Microbiol.* **25**, 1052–1058.

Woode, G., Zheng, S., Melendy, D., and Ramig, R. (1989). Studies on rotavirus homologous and heterologous active immunity in infant mice. *Viral Immunol.* **2**, 127–132.

Woods, P., Gentsch, J., Gouvea, V., Mata, L., Simhon, A., Santoosh, M., Bai, Z., Urasawa, S., and Glass, R. (1992). Distribution of serotypes of human rotavirus in different populations. *J. Clin. Microbiol.* **30**, 781–785.

Wright, P., Tajima, T., Thompson, J., Kokubun, K., Kapikian, A., and Karzon, D. (1987). Candidate rotavirus vaccine (rhesus rotavirus strain) in children: An evaluation. *Pediatrics* **80**, 473–480.

Wright, P., King, J., Araki, K., Kondo, Y., Thompson, J., Tollefson, S., Kogayashi, M., and Kapikian, A. (1991). Simultaneous administration of two human-rhesus rotavirus reassortant strains of vp7 serotype 1 and 2 specificity to infants and young children. *J. Infect. Dis.* **164**, 271–276.

Wyatt, R., Mebus, C., Yolken, R., Kalica, A., James, H., Kapikian, A., and Chanock, R. (1979). Rotaviral immunity in gnotobiotic calves: heterologous resistance to human virus induced by bovine virus. *Science* **203**, 548–550.

Wyatt, R., Kapikian, A., and Mebus, C. (1983). Induction of cross-reactive serum neutralizing antibody to human rotavirus in calves after in utero administration of bovine rotavirus. *J. Clin. Microbiol.* **18**, 505–508.

Yolken, R., and Murphy, M. (1982). Sudden infant death syndrome associated with rotavirus infection. *J. Med. Virol.* **10**, 291–296.

Yolken, R., Wyatt, R., and Zissis, G. (1978a). Epidemiology of human rotavirus types 1 and 2 as studied by enzyme-linked immunoabsorbant assay. *N. Engl. J. Med.* **299**, 1156–1161.

Yolken, R., Wyatt, R., Mata, L., Urratia, J., Garcia, B., Chanock, R., and Kapikian, A.
(1978b). Secretory antibody directed against rotavirus in human milk—measurement by means of enzyme-linked immunosorbent assay. *J. Pediatr.* 93, 916–921.
Zheng, B., Ma, G., Tam, J., Lo, S., Ng, M., Lam, B., Yeung, C., and Lo, M. (1992). The effects of maternal antibodies on neonatal rotavirus infection. *Pediatr. Infect. Dis. J.* 10, 865–868.
Zissis, G., Lambert, J., Marbehant, P., Marissens, D., Lobmann, M., Charlier, P., Delem, A., and Zygraich, N. (1983). Protection studies in colostrum-deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. *J. Infect. Dis.* 148, 1061–1068.